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ABSTRACT OF THE DISSERTATION
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Pathological bone loss in human disease such as arthritis is largely due to excessive
osteoclast recruitment as a consequence of localized inflammation. Innate immune cells, namely
neutrophils and macrophages, infiltrate the joint space and release pro-inflammatory cytokines as
well as proteases to drive local tissue damage and inflammation. Importantly, IL-1 and TNF- in
particular act on the synovial fibroblasts as well as directly on osteoclast precursors to potently
augment osteoclast differentiation and thus bone resorption. Current therapeutics to treat
pathological bone loss are widely unsuccessful at targeting both the resorptive and inflammatory
components of disease. We have previously demonstrated that phospholipase C gamma-2
(PLCγ2) regulates both the osteoclast and innate immune cell functions. PLCγ2-/- mice are
osteopetrotic resulting from defective OC formation and are protected from inflammatory bone
loss due to impaired innate immune responses. While PLCγ2 function can be specifically
repressed in the osteoclast via SH2 domain targeting, this approach does not block inflammation
in vivo. Thus we sought to identify specific downstream targets of PLC2 that could regulate
both the osteoclast and innate immune responses in arthritis.
vii

By a gene array approach, we identified the previously undescribed protein Tmem178 as
a novel PLC2 effector whose expression is highly induced by RANKL stimulation, integrinmediated adhesion, and TLR activation in WT but not PLC2-/-macrophages. Importantly,
Tmem178 expression is confined to macrophages and osteoclasts and not in other bone marrowderived cells or immune cell types such as T cells. In surprising contrast to the osteopetrotic
phenotype of PLC2-/- mice, Tmem178-/- mice are osteopenic in basal conditions and are more
susceptible to inflammatory bone loss, owing to enhanced osteoclast formation. We also find that
Tmem178-null mice succumb faster to endotoxin-induced sepsis due to an increase in
inflammatory cytokine production by macrophages. Mechanistically, Tmem178 localizes to the
endoplasmic reticulum membrane where it interacts with the Ca2+-sensing protein Stim1. In the
ER, Tmem178 acts to restrain Ca2+ release, thus controlling activation of the transcription factor
NFAT which is central to both osteoclast differentiation and pro-inflammatory cytokine
production. Importantly, downregulation of Tmem178 is observed in human CD14+ monocytes
exposed to plasma from systemic juvenile idiopathic arthritis patients. This defective Tmem178
expression correlates with augmented osteoclastogenesis in vitro and erosive disease in vivo,
suggesting that Tmem178 may also play a fundamental role in controlling arthritic disease in
humans. In sum, this dissertation identifies the first known function of Tmem178 in any cell type
and positions Tmem178 as an essential regulatory component in both the inflammatory and
erosive arms of pathological bone loss.
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Chapter 1. Introduction
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1.1 Background
Part I. The osteoclast and bone remodeling
The musculoskeletal system, comprised of bone, cartilage, and muscle, serves three
essential functions in the organism. The mechanical function of the skeleton is required to
mediate mobility and stability of the organism. Secondly, the skeleton serves to harbor and shield
the bone marrow within the vertebrae and long bones, as well as protect the internal organs
housed within the rib cage and skull. Lastly, the bone itself is a reservoir of mineral stores,
namely calcium and phosphate, which are released from the skeleton during bone turnover and
regulate whole-body metabolism. In these ways, the skeleton is a dynamic organ which exerts
not only its obvious mechanical and structural functions, but also participates in cross-talk with
the endocrine, immune, digestive, and nervous systems (1, 2).
The bone is comprised of an inorganic and organic matrix. The latter is made up
primarily of type I collagen, as well as numerous growth factors including osteopontin, bone
sialoprotein, osteonectin, osteocalcin, and glycosaminoglycans. The inorganic matrix of the
bone, which is laid down on top of the organic matrix, is comprised of carbonated
hydroxyapatite. Deposition of these organic and inorganic is carried out by osteoblasts (OB)
derived from mesenchymal progenitors (MPs). OBs both form and mineralize the skeleton
during embryonic and postnatal development, skeletal remodeling and bone turnover throughout
life (3). In vivo, mature OBs are characterized by their cuboidal morphology on the bone surface
which distinguishes them from flat, bone-lining cells. In vivo, it is believe that these mature OBs
form the bone, while the more immature OBs produce RANKL, a factor required for osteoclast
(OC) differentiation (4). The OC is the sole bone-resorbing cell that is required for proper
shaping of the bone and bone turnover (5). The coupling of OC and OB activity is central to
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skeletal formation and maintenance. As the body of this work focuses on the OC, OB
differentiation and function will not be discussed in detail but are well-described in detail in
references (6-8).
Osteoclasts and skeletal resorption
Osteoclasts (OCs) are the unique multinucleated, bone-resorbing cells that form from the
fusing of mononuclear precursors (9). As depicted in Figure 1.1, OCs originate from
hematopoietic precursors in the bone marrow which first encounter the cytokine macrophage
colony stimulating factor (M-CSF) which pushes the precursors to the common myeloid
progenitor (CMP). M-CSF supports the proliferation and survival of the myeloid precursors and
also upregulates expression of receptor activator of NF-kB (RANK), the receptor for RANK
ligand (RANKL), the key osteoclastogenic cytokine (10). Importantly, OBs present RANKL on
their surface, and direct interaction of OB with OC precursors is the main driver of OC
differentiation (11, 12). Mononuclear preOC begin expressing tartrate resistant acid phosphatase
(TRAP), which is commonly used as a marker of OC both in vitro and in vivo. These
mononuclear preOCs then fuse to form large, multi-nucleated OC which are fully mature when
attached to the bone surface (13, 14). It is believed that in vivo OCs have a relatively short life
span and undergo apoptosis following bone resorption, although the inability to perform lineage
tracing experiments of OCs in vivo has limited the complete understanding of this cell type. OCs
are mature and active on the bone surface where they polarize and adhere tightly to the bone via
v3 integrin attachment. v3 integrin is required for proper bone resorption and specifically
recognizes bone matrix proteins including fibronectin and osteopontin to form a tight sealing
zone; it is within this sealing zone that the OC resorbs the bone (15-19).
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After the mature OC attaches to the bone and establishes the sealing zone, the ruffled
border structure is formed. The OC uses vesicle-mediated secretion of proteases and proteinases
to resorb the bone. The fusion of these vesicles with the cell’s plasma membrane forms the
appearance of a ruffled border made up of long projections of the plasma membrane into the
bone matrix (20). Following the formation of the ruffled border, the OC first resorbs the
inorganic matrix of the bone. OCs express protein pumps and chloride channels to form HCl in
the resorptive lacunae and dissolve the hydroxyapatite of the bone (21-23). The organic matrix of
the bone is then dissolved by proteolytic enzymes, namely matrix metalloproteinase 9 and
cysteine proteases, which break down collagen (24). Cathepsin K is particularly required for
resorption of the organic matrix, as the null mice present with severe osteopetrosis owing to
defective resorption (25-27). Interestingly, Cathepsin K is released in discrete lysosomal vesicles
independent of MMP9, although the exact regulatory mechanisms of Cathepsin K-containing
vesicles are not yet understood (28). Following resorption, the OC must also remove the
degradation products from the resorptive lacunae. Collagen fibers and calcium are taken up by
the OC by vesicle-mediated endocytosis, and released from the top of the cell via transcytosis on
the opposite side of the ruffled border.
Bone remodeling
The term “bone remodeling” is used to describe healthy skeletal turnover that occurs in adult
organisms. This resorption of old bone and replacement with new bone is required to ensure
skeletal integrity throughout life and is also required for bone healing in the instance of fracture
or injury. Importantly, OC and OB functions are coupled during bone remodeling so that bone
resorption and deposition are synchronized and equilibrated (Figure 1.2). Dysregulation of this
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coupling underlies skeletal pathologies such as osteoporosis. Bone remodeling is broken down
into 3 steps: initiation, transition, and termination (29, 30).
The initiation of bone remodeling can be spurred by numerous physiological changes
including hormonal changes, deficits in serum calcium, mechanical load, or fractures in the bone.
First, OC precursors must be recruited to the bone in response to chemoattractants including
CCL2, also known as monocyte chemoattractant protein 1 (MCP-1) (31, 32). CCL2, which
engages CCR2 or CCR4 on the OC precursor, is especially important and prevalent during
inflammatory conditions, as its expression by OBs is induced by TNF- and IL-1. Additionally,
vascular endothelial cells in the bone as well as OBs can produce stromal derived growth factor
(SDF-1) which binds to CXCR4 on OC precursors (33, 34). After being recruited to the site of
bone remodeling, OC precursors are mature and active on the bone surface, leading to the
transition phase of remodeling.
During the transition phase of bone remodeling, OC activity is coupled to OB bone
deposition. While resorbing the bone, the OC initiates the release of bone-derived growth factors
to stimulate the OB. These factors include TFG, BMPs, and insulin-like growth factor II (IGFII) (35, 36). Some molecules produced by the OCs themselves may also act on OBs. For
example, sphingosine 1-phosphate (S1P) is secreted by OCs and can signal to OBs to enhance
their recruitment and survival (37). The induction of OB activity also suppresses OC activity.
Specifically, OBs express EphB4 which binds to ephrin B2 on the OC, inducing bi-directional
signaling to promote OB proliferation while suppressing osteoclastogenesis (38). Ultimately,
OCs undergo apoptosis during the transition phase while bone deposition predominates.
During the termination phase, OBs actively form new bone, a slow process which can last
approximately 3 months in humans. During this phase, OC differentiation and activity must be
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suppressed to allow for matrix deposition. For this purpose, OBs produce osteoprotegerin (OPG),
the soluble decoy receptor for RANKL. OPG production by the OBs is largely turned on through
both NOTCH and Wnt signaling pathways (39, 40). Mice lacking OPG present with
osteoporosis due to excessive bonne resorption (41). At the conclusion of the termination phase,
OBs are believed to have 3 possible fates: undergo apoptosis, become inactive bone-lining cells,
or become embedded within the bone matrix as osteocytes. The molecular mechanisms
determining OB fate are not well understood, however. While all the physiological roles of
osteocytes are still being elucidated, it is known that osteocytes secrete fibroblast growth factor23 (FGF23), which acts on the kidney to regulate serum phosphorous levels and may also be
important to bone formation induced by mechanical loading (42-44). The lack of a specific
molecular marker to distinguish osteocytes from OBs, however, has precluded the successful
generation of osteocyte-specific genetic models.
Part II. Osteoclast signaling pathways
As stated above, OCs arise from hematopoietic precursors in the bone marrow (45). The
cytokines M-CSF and RANKL are required for precursor survival, proliferation, and
commitment to the OC lineage. Exposure to M-CSF first pushes the cells to the myeloid lineage.
While the exact OC precursor in vivo is unknown, several groups have characterized myeloid
cells with high osteoclastogenic potential with the surface markers CD11b–/loCD115+CD117+
(46, 47). Further stimulation of these cells with the cytokine RANKL commits them to the OC
lineage. During the early phases of osteoclastogenesis, the cells exit the cell cycle and cease
dividing, at which point they will become terminally differentiated OC (48).
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M-CSF signaling
M-CSF, encoded by the gene Csf1, is produced by OBs in both a membrane and soluble
form. The necessity of M-CSF specifically in the context of the OC and bone is underscored by
the severe osteopetrotic phenotype of op/op mice which harbor a mutation in Csf1. Op/op mice
fail to develop OC in vivo, leading to extremely high bone mass and impaired tooth eruption
(49). Dai and colleagues also deleted the receptor for M-CSF, c-fms, and found a similar
impairment in OC differentiation and bone resorption in vivo (50).
c-Fms is a receptor tyrosine kinase which undergoes dimerization and
autophosphorylation following ligation to M-CSF. This autophosphorylation of tyrosine residues
in the cytoplasmic tail provides a docking site for the SH2 motif of Src family kinases, namely cSrc. This signaling at the receptor activates 2 major intracellular signaling pathways: PI3K and
MAPK (51, 52). PI3K is recruited directly to the receptor and activates downstream protein
kinase B (Akt), which in turn stimulates gene transcription for cell proliferation via cyclin
proteins. Akt also signals to mTOR to promote anti-apoptotic pathways and cell survival. The
MAPK pathway induces extracellular related kinase (ERK) activation, which turns on the
cascade of activation leading to p38, c-Jun, and JNK2 phosphorylation. This pathway is
ultimately necessary to induce the transcription factor Mitf that turns on the anti-apoptotic
protein Bcl-2 (53). In fact, overexpression of Bcl-2 is sufficient to rescue the high bone mass
phenotype of the op/op mice (54). Through these pathways, M-CSF is indispensable to support
the survival and proliferation of OC precursors, and importantly, also up-regulates their
expression of RANK.
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RANKL signaling
RANKL is a member of the TNF superfamily that is wholly necessary for OC
differentiation. Mice lacking RANKL or its receptor RANK present with a complete lack of OCs
and failure in tooth eruption (12, 55). RANKL exists as both membrane-bound form, such as it is
found on OB and perhaps osteocytes, and also in secreted form following cleavage by ADAM (a
disintegrin and metalloprotease domain) and matrix metalloproteases (56, 57). Secreted RANKL
is produced by T cells in the inflamed synovium and appears to contribute significantly to joint
destruction during rheumatoid arthritis (58). The majority of RANKL is present in the
membrane-bound form, however, and thus osteoclastogenesis requires direct cell-to-cell contact.
The binding of RANKL monomers to the receptor RANK, a TNF superfamily member,
induces receptor trimerization. Downstream signaling is dependent on protein scaffolding at the
receptors’ cytoplasmic tail, which harbors no intrinsic enzymatic activity of its own. RANK can
recruit several isoforms of the TNF-related factor (TRAF) family of adaptor proteins (59). Of
these, TRAF6 is particularly important, as TRAF6-null mice present with high bone mass owing
to defective OC differentiation (60). A second adaptor, Gab2, also appears to be critical in
protein scaffolding at RANK, as Gab2-/- mice also suffer from osteopetrosis (61-63). The
assembly of these molecules initiates downstream signaling of MAPK and NF-kB pathways that
modulate both OC differentiation as well as bone resorption (Figure 1.3).
NF-kB
The family of NF-kB transcription factors, comprised of p50, p52, p65 (also known was
RelA), RelB, and c-Rel, can be activated via 2 distinct pathways referred to as the classical and
alternative pathways (64, 65). Both classical and alternative NF-kB are activated by RANKL
signaling (Figure 1.4). In the classical pathway, the IKK kinase complex, composed of IKK,,
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and , is activated by TRAF6, and in turn phosphorylates IKB66). In steady-state conditions,
IKB functions to retain the NF-kB family member p50 in the cytoplasm in complex with p65 or
cRel. Phosphorylation of IKB targets the protein for proteosomal degradation, allowing the
release and nuclear translocation of the p50-p65/cRel dimer and activation of NF-kB responsive
genes. On the other hand, the alternative pathway is dependent on the kinase NIK, which in
steady state conditions is rapidly degraded via TRAF3-mediated ubiquitination. Recruitment of
TRAF3 to RANK, however, allows for NIK stabilization and its activation of the IKK complex.
IKK in turn activates the processing of p100 to the active form p52 (66, 67). RelB pairs with
p52, and the dimer can then translocate to the nucleus and activate gene transcription.
Mice deficient in both p50 and p52 and thus totally lacking NF-kB signaling present with
osteopetrosis due to lack of OC differentiation (68, 69). RelA knockout mice have significantly
fewer OC in basal conditions due to increased apoptosis and are protected from inflammatory
osteolysis (70). Similarly, RelB-/- mice fail to form OC when challenged with TNF- in vivo,
and RelB-/- precursors cannot undergo osteoclastogenesis in vitro (71). Thus, both the classical
and alternative pathways are necessary for OC differentiation and function. While induction of
the classical pathway occurs very rapidly and transiently within minutes of RANKL stimulation,
the alternative pathway is turned on slowly over the course of hours and is sustained. Likewise,
classical and alternative NF-kB signaling appear to regulate different processes during
osteoclastogenesis. Classical NF-kB promotes OC precursor survival while alternative signaling
contributes to differentiation.
cFos/AP-1
In addition to NF-kB, the transcriptional complex AP-1 is also essential to OC formation
(Figure 1.5). During osteoclastogenesis, it appears that multiple signaling pathways synergize to
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activate AP-1 induction, including NF-kB, calcium activation of CREB, and the MAP kinase
component p38 (72, 73). Among the members of the AP-1 family, c-Fos is most important to the
OC, as evidenced by the severe high bone mass and lack of OCs in the c-Fos -/- mouse (74). It is
unclear why c-Fos is specifically important in the OC compared to other AP-1 proteins including
Fra-1, JunB, or c-Jun, and which genes are uniquely targeted by c-Fos for osteoclastogenesis
(75). Interestingly, it has recently been observed that c-Fos induction during osteoclastogenesis is
more strongly dependent on M-CSF signaling compared to RANKL signaling cascades, and this
pathway appears to be dependent on PLC-mediated generation of diacylglycerol (Zamani et al.,
in press).
Co-stimulatory receptors in osteoclastogenesis
The OC is wholly dependent on ongoing intracellular Ca2+ fluxes to induce and support
differentiation. While Ca2+ fluxes during osteoclastogenesis are known to be compulsory to
differentiation and function, these signals are not actually originated by RANK directly. It was
previously known that in immune cells, phospholipase C gamma (PLC) generates Ca2+ fluxes
downstream of co-stimulatory molecules (76). In the OC, co-stimulatory receptors are associated
with adapter molecules, namely DAP12 and FcR, containing an Immunoreceptor tyrosine-based
activation motif (ITAM) which enables downstream signaling (77).
In the OC, DAP12 and FcRare ITAM-containing adaptors which appear to be essential
to osteoclastogenesis. While the deletion of either of these genes alone does not result in a
significant bone phenotype, double knock out mice present with severe osteopetrosis, suggesting
that these co-stimulatory pathways may compensate for one another in vivo (78-81). ITAMcontaining proteins do not bind ligand themselves but are coupled to receptors. In the OC,
DAP12 couples to TREM2, TREM3, SIRb1, and MDL-1. Interestingly, patients with mutations
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in either TREM2 or DAP12 suffer from recurring fractures and osteolytic lesions (82). Similarly,
TREM2-/- mice show low bone mass due to accelerated OC formation in the face of
dysregulated -catenin (83). These studies suggest that TREM2 may be the most important costimulatory molecule in humans. The ligand for TREM2 is not yet known. On the other hand,
FcR associates with the receptor OSCAR, which has recently been shown to bind collagen in
the matrix .
During osteoclastogenesis, signaling at RANK cross-talks with the ITAM-containing
adaptors to initiate downstream PLC-dependent signaling cascades (Figure 1.6). In the OC
specifically, two Src family kinases, c-Src and Fyn, which are recruited to RANK, first
phosphorylate the tyrosine residues of the ITAM domain. Deletion of c-Src results in
cytoskeletal defects in the OC but not impaired differentiation, however, so it is currently unclear
which Src-family kinases can activate ITAM signaling in the OC to modulate osteoclastogenesis.
Following phosphorylation of the ITAM, the kinase Syk is recruited via its SH2 domain.
Similarly to the phenotype of c-Src knock out cells, deletion of Syk disrupts the OC cytoskeleton
but does not abrogate differentiation, suggesting that other kinases may be able carry out this
step. Syk activation recruits the scaffolding proteins BLNK and SLP76, and this signalosome
complex leads to eventual phosphorylation of PLC, turning on its catalytic activity.
As active lipases, PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into the
second messengers inositol-3-phophate (IP3) and diacylglycerol (DAG). Through these
pathways, PLC activates downstream Ca2+ fluxes and DAG-dependent signaling effectors
including PKCs, respectively (85). There are two isoforms of PLC: PLC1 which is
ubiquitously expressed and PLC2 which is expressed only in hematopoietic lineages. While
PLC1-/- mice do not survive, PLC2-deficient mice are viable (86). These mice are
11

characterized by a severe osteopetrotic phenotype owing to defective OC differentiation.
Surprisingly, although PLC1 is intact in these mice, PLC1 cannot compensate for the loss of
PLC2. In vitro experiments revealed that impaired osteoclastogenesis in the absence of PLC2
is due to defective NFATc1 upregulation (87). Interestingly, overexpression of NFATc1 in
PLC2-/- cells can rescue OC formation but not bone resorption (88). Further studies showed
that DAG signaling to PKCd downstream of PLCg2 regulates Cathepsin K-containing vesicle
secretion. DAG remains at the membrane and can activate multiple downstream effectors,
including protein kinase C- delta (PKC) in the OC. This DAG-PKC pathway regulates
secretion of Cathepsin K-containing vesicles in the mature OC (28).
Ca2+ fluxes in osteoclastogenesis
The OC is wholly dependent on sustained intracellular Ca2+ fluxes for differentiation
(Figure 1.7). RANKL-induced activation of PLC2 leads to the generation of IP3, which diffuses
through the cytosol and binds the IP3 receptor (IP3R) on the ER membrane. IP3Rs multimerize
to form a Ca2+ channel, allowing release of Ca2+ from ER stores (89). In the OC, it appears that
IP3R isoforms 1, 2, and 3 are expressed. The osteopetrotic phenotype of IP3R2/3 doubly
deficient-mice suggest that these isoforms may be most important Ca2+ fluxes in the OC,
however (90). Stim1 is an ER Ca2+ sensor that harbors an EF-hand Ca2+ -binding domain. When
Ca2+ levels decline in the ER, Ca2+ is dissociated from Stim1, inducing a conformational change
and its translocation within to ER-plasma membrane junctions (91-95). Here, Stim1 binds to and
activates the protein Orai1 (96). Orai1 is the pore-forming subunit of the Ca2+ release activated
Ca2+ (CRAC) channel. Extracellular Ca2+ enters the cell’s cytoplasm through the CRAC channel
(97-99). ER Ca2+ stores are replenished via active transport of Ca2+ by the Sarco-endoplasmic
reticulum Ca2+ ATPase (100, 101). Through these mechanisms, intracellular Ca2+ fluxes are
12

sustained in the OC. Genetic deletion of Orai1 or SERCA2, as well as pharmacological
inhibition of Stim1, each abolish Ca2+ fluxes and OC differentiation (101-103).
Nfatc1 as the OC master transcription factor
Following RANKL stimulation, NF-kB, AP-1, and Ca2+ signaling pathways all contribute
to the induction of NFATc1, a member of the family of NFAT transcription factors. NFAT
proteins are sequestered in the cytosol in basal conditions due to masking of their nuclear
localization sequence. De-phosphorylation by the calcium-dependent phosphatase calcineurin
results in a conformational change to allow NFAT nuclear translocation (104). Within the
nucleus, NFAT is also regulated by phosphorylation by a number of kinases including GSK3
(105, 106). This phosphorylation induces NFAT nuclear export to the cytosol. Interestingly,
NFATc1 can also bind to its own promoter to auto-amplify its transcription and protein
expression (107).
The importance of NFATs during osteoclastogenesis is evidenced by both
pharmacological and genetic studies. Cyclosporin A, an inhibitor of calcineurin and therefore
NFAT, strongly suppresses osteoclastogenesis in vitro. Although NFATc1-/- mice are
embryonic lethal, NFATc1-null embryonic stem cells are unable to undergo osteoclastogenesis
(108). More recently, conditional deletion of NFATc1 via Mx1-cre was demonstrated to increase
bone mass in mice by inhibiting OC formation (109). NFATc1 has been deemed the “master
transcription factor” of osteoclastogenesis, as it directly regulates OC-specific genes including
TRAP, calcitonin receptor, Cathepsin K, and 3 integrin (107, 110, 111).
NFATc1 is regulated by several transcriptional repressors that control its activation.
Interferon regulator factor-8 (IRF8) and Bcl6 are constitutively bound to the NFATc1 promoter,
and their expression is down-regulated within 24 hours of RANKL stimulation (112-115).
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Interestingly, Bcl6 is down-regulated via the RANKL-dependent induction of its repressor
Blimp1 (114). Thus, RANKL-induced alleviation of transcriptional repression allows robust
NFATc1 activation and auto-amplification.
Part III. Osteo-immune activation in arthritis
During pathological bone loss as occurs in arthritic conditions, both the bone and immune
cells are activated. This osteo-immune cross-talk has become increasingly recognized as a driver
of debilitating joint erosion. Both the innate and adaptive immune cells participate in this osteoimmune activation. In the state of an inflammatory trigger, innate immune cells, namely
neutrophils, mast cells, and macrophages, are rapidly recruited to the joint. Importantly, multiple
signaling pathways, including NF-kB, MAPK, and PLC2/Ca2+/NFAT, are shared in the
response of both bone and immune cells and both to inflammatory cytokines (116).
Inflammatory cytokines fuel bone loss
Arthritic patients show high levels of inflammatory cytokines both in circulation and
locally in the joint. TNF- and IL-1 in particular upregulate RANKL expression by OBs and
stromal cells, thereby increasing osteoclastogenesis (57, 117, 118). Moreover, these cytokines
can also act directly on the OC precursor and synergize with RANKL to amplify OC
differentiation (119-122). Both anti-TNF and IL-1 receptor antagonist are used as treatments in
arthritic conditions, although not all patients are responsive to cytokine inhibition. The cytokine
IL-17, produced by Th17 cells, is also believed to be pathogenic in psoriatic arthritis by
increasing the production of RANKL by T cells and B cells (123).
The role of IL-6 and IFN-during pathological bone loss is less clear. IL-6 deficient mice
show no OC phenotype in basal conditions but are protected from ovariectomy-induced bone
less (124, 125). Similarly, increased IL-6 levels have been observed in post-menoposal women,
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suggesting that this cytokine may specifically contribute to estrogen-deficient bone loss (126).
The role of IFN- in bone is also unclear. In mice but not humans, IFN- inhibits
osteoclastogenesis in vivo in arthritic conditions (127). However, IFN- positively regulates
macrophage activation and consequent inflammatory cytokine production (128), and therefore
could indirectly increase osteoclastogenesis.
Immune cells in bone
Both adaptive and innate immune responses contribute to a pro-resorptive environment in
the joint space. Adaptive immune responses by T cells and B cells through the recognition of
specific auto-antigens and production of auto-antibodies can also contribute to uncontrolled
immune responses. T cells produce IFN- which amplifies the innate pro-inflammatory response
as well as antigen presentation (129). Additionally, T cells can secrete RANKL to activate OCs
(130). B cells also have more recently been proposed to produce RANKL themselves (131, 132).
Through these pathways, the immune response fuels OC over-activity and also amplifies the
innate immune response, allowing progressive joint destruction.
Innate immune cells, including neutrophils, mast cells, and monocytes/macrophages, are
the first cells to infiltrate the joint during arthritic conditions. Through the production of
inflammatory cytokines, reactive oxygen species, and release of proteolytic granules, these cells
induce local tissue damage, recruit more immune cells to the joint, and activate
osteoclastogenesis (133). Unlike the adaptive immune cells, which edit their receptors to
recognize specific antigens and can develop immunological memory, the innate response is
dependent on fixed pattern recognition receptors (PRRs) which are fixed to identify discreet
pathogen- associated molecular patterns (PAMPs) and elicit a rapid response, as well as Fc
receptors which bind the Fc fragment of antibodies. In the context of inflammatory bone loss,
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innate immune cells are activated via Toll-like receptor (TLR) ligands (including bacterial, viral,
and fungal components as well as endogenous TLR ligands), complement deposition, and
immune complex formation(134-136). In animal models of inflammatory arthritis, the depletion
or inhibition of neutrophils or macrophages alone is sufficient to protect the joint from
infiltrating leukocytes and bone loss, underscoring the importance of these cells types in arthritic
disease (137-139). Natural killer (NK) cells are innate cytotoxic cells that are capable of directly
killing infected cells by the release of granules containing perforin and proteases. NK cells are
found in the synovial fluid of rheumatoid arthritis patients and also express both M-CSF and
RANKL, thereby supporting osteoclastogenesis from monocytes in the joint (140) Lastly,
dendritic cells (DCs) are the bridge between the innate and adaptive response. DCs take up
antigen in the periphery and then migrate to the lymph nodes where they present antigen to Tcells, thus activating an antigen-specific response (141). DCs are present in the synovial fluid of
RA patients where they appear to promote T cell-inflammatory responses, and DC migration and
antigen presentation are wholly required in animal models of antigen-induced arthritis (142,
143). While much more work is ongoing to understand the contribution of each of these cell
types to arthritic diseases, this thesis will focus on the monocyte/macrophage lineage for both its
direct contribution to the OC lineage and pro-inflammatory functions.
Macrophage development and function
Tissue-resident macrophages are professional antigen presenting cells which maintain
homeostasis in physiological conditions, rapidly respond to an immunological challenge, and
mediate tissue repair and restoration. From the hematopoietic stem cell (HSC), there are 4 known
intermediates leading to macrophage differentiation: common myeloid progenitors (CMP),
granulocyte and macrophage progenitors (GMP), macrophage and dendritic cell progenitors
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(MDP), and finally the common monocyte progenitors (CMoP). Bone marrow and splenic red
pulp macrophages are believed to actually be established before birth and are independently
maintained. On the other hand, splenic marginal zone macrophages are continually renewed by
differentiating monocytes in circulation (144). In the context of arthritis, synovial macrophages
and inflammatory monocytes are derived from the circulating population, whose numbers are
increased in arthritic patients (145).
In tissues, macrophages are highly phagocytic cells that are on watch to engulf foreign
material, cellular debris, as well as microbial and viral particles. The engulfed material is housed
in a phagosome which fuses with a lysosome of low pH, allowing digestion in the
phagolysosome. Through this pathway, macrophages are highly efficient at clearing unwanted
matter from the tissue to prevent or control an infection before the adaptive immune response is
mounted. As professional APCs, macrophages also express both MHC Class I and Class II
molecules to present endocytosed and processed antigen to CD8+ and CD4+ T cells,
respectively, thus stimulating a specific adaptive immune response (144, 146).
Macrophages can further dictate the immune response by producing a number of
cytokines, both pro- and anti-inflammatory. In the past, macrophages were segregated into M1
and M2 subtypes, reflecting their contributing roles to T helper cell 1 and T-helper cell 2
responses, respectively. In these classifications, M1 macrophages are generated by exposure to
IFN-g in combination with the bacterial cell wall component lipopolysaccharide (LPS) or TNF.
M1 macrophages are strongly pro-inflammatory and anti-tumorigenic through the production of
IL-1, TNF, IL-6, and iNOS, as well as enhanced MHC Class II antigen presentation capacity. On
the other hand, M2 macrophages result from stimulation with some combination of IL-4, IL-13,
or IL-10. Stimulation with these cytokines upregulates production of arginase and IL-10 and
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increases expression of the scavenger receptor CD206. These M2 macrophages participate in
allergic and anti-parasitic responses, immunoregulation, and perhaps tumor promotion (146).
Macrophages in rheumatic disease
Monocyte and macrophage numbers are elevated in arthritic patients and can contribute
to disease both through their inflammatory actions and their differentiation into bona fide boneresorbing OCs. One model disease in which this monocyte/macrophage population is playing an
essential yet enigmatic role is systemic juvenile idiopathic arthritis (sJIA). sJIA is an episodic
auto-inflammatory disease that, unlike other arthritic subtypes, is primarily driven by innate
immune cells. Expanded monocyte numbers, particularly during episodes of disease flare, are
observed in sJIA patients. The trigger of this excessive monocyte response is unknown. These
monocytes may be activated by an infectious stimuli or endogenous TLR ligands inducing a proinflammatory response. Intriguingly, M2-like monocytes appear during episodes of disease flare
and persist into the transition to a quiescent state, suggesting that this M2 population arises in an
attempt to ameliorate the systemic inflammatory environment (147-151). In fact, it is still
unknown whether the excessive pro-inflammatory response or defective anti-inflammatory
response truly underlies the pathologies of sJIA. Thus, a better understanding of the signaling
pathways which modulate the plasticity of the monocyte/macrophage lineage and potentiate a
switch to an anti-inflammatory response would be highly applicable to sJIA, in addition to
numerous macrophage-mediated pathologies.
Approximately 10% of sJIA patients develop macrophage activation syndrome (MAS),
which is responsible for the majority of the morbidities associated with sJIA. The onset of MAS
is sudden, and patients present with high fever, hepatosplenomegaly, lymphadenopathy,
cutaneous and mucosal bleeding, pancytopenia, as well as central nervous system, cardiac, and
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renal involvement. Patients have very high levels of inflammatory cytokines, TNF-, IL-1, IL-6,
IL-18, as well as IFN- in the serum. Importantly, MAS is so-named due to a massive influx of
activated macrophages in the bone marrow, liver and spleen. It is actually unknown if this
increase in macrophages is driving pathogenesis or is an attempt to control a dysregulated
adaptive immune response (152). The sJIA/MAS field is currently lacking a clear picture of how
the activated monocyte/macrophage population functions at both a cellular and molecular level
during the onset and course of disease.
Part IV. PLC2 as an osteo-immune modulator
PLC structure and function
PLC is a 150kDa protein containing both an active lipase domain as well as several
scaffolding motifs to facilitate protein interactions. The catalytic domain is split into 2 hemi
domains that are separated and thus non-functional in the resting state. PLCphosphorylation
downstream of receptor activation induces a conformational change to bring together the split
catalytic domain. The scaffolding domains of PLC include tandem SH2 domains, an N-terminal
PH domain, a split PH domain, and an SH3 domain. The split PH domain comes together in
PLC’s active conformation, but its exact role is unknown. The N-terminal PH domain is
responsible for PLC membrane and substrate targeting by binding directly to PIP2. The tandem
SH2 domains appear to be necessary for protein scaffolding at the receptor complex by binding
to phosphorylated tyrosine motifs, while the SH3 domain recognizes the conserved PxxP motif
on binding partners. Finally PLC also harbors a C2 calcium-binding domain at its C-terminus
which also participates in membrane binding (85).
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PLC Signaling in Osteo-Immunology
In order to better target both the overactive immune and OC responses underlying
inflammatory osteolysis and arthritis, it is necessary to identify common signaling components
shared by these systems. PLC2 is such a critical mediator of the osteoimmune system owing to
its requirement to both innate immune response and OC formation and function. PLC2-/- mice
are osteopetrotic due to a defect in both OC formation as well as function (28, 87). Interestingly,
both the enzymatic and scaffolding functions of PLC2 play distinct yet essential roles in
promoting osteoclastogenesis (87). While PLC2’s catalytic activity is necessary to stimulate
Ca2+ fluxes leading to NFATc1 activation, its scaffolding domains are required for NF-kB and
AP1 induction.
In addition to a pronounced bone phenotype, PLC2-/- mice exhibit defects in neutrophil,
macrophage, dendritic cell, and NK cell responses. More specifically, PLC2 deletion prevents
the induction of IL-1, TNF-, and IL-6 by macrophages stimulated by TLR2 and TLR4 ligands
(153, 154). Importantly, PLC2-/- mice are protected from inflammatory cytokine production in
the K/BXN serum transfer model of arthritis, specifically due to impaired inflammatory cytokine
expression (155). While PLC2 seems an appealing therapeutic target, its extensive homology
with other PLC isoforms presents a challenge for specific targeting in vivo. Therefore, we must
focus on developing novel methods to therapeutically target PLC2 and its downstream signaling
pathways. In this thesis, I demonstrate a novel method of targeting PLC2 via its unique SH2
domains to protect from osteolysis. In chapters 3 and 4, I describe a novel PLC2-dependent
protein, Tmem178, and its surprising role in the regulation of inflammatory bone loss and
macrophage activation.
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1.2 Figures

Figure 1.1 Osteoclast differentiation from myeloid precursors
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Figure 1.2 Osteoclast-osteoblast coupling in bone remodeling
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Figure 1.3 Protein scaffolding at RANK initiates NF-kB and MAPK cascades
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Figure 1.4 Classical and alternative NF-kB pathways
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Figure 1.5 RANK activates MAPK signaling to induce cFos and the AP1
transcriptional complex
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Figure 1.6 RANK cross-talks with ITAM-coupled receptors to activate PLC2
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Figure 1.7 PLC2 activates ER Ca2+ release coupled to Ca2+ entry, leading to
cytosolic Ca2+ fluxes driving NFATc1 activation
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2.2 Abstract
Phospholipase C gamma β (PLC β) is a critical regulator of innate immune cells and
osteoclasts (OCs) during inflammatory arthritis. Both the catalytic domain and the adaptor motifs
of PLC β are required for OC formation and function. Due to the high homology between the
catalytic domains of PLC β and the ubiquitously expressed PLC 1, molecules encompassing the
adaptor motifs of PLC β were designed to test the hypothesis that uncoupling the adaptor and
catalytic functions of PLC β could specifically inhibit osteoclastogenesis (OCG) and bone
erosion. Wild-type (WT) bone-marrow macrophages (BMM) that over-express the tandem SH2
domains of PLC β (SHβ(N+C)) failed to form mature OCs and resorb bone in vitro. Activation
of the receptor activator of NF-κB (RANK) signaling pathway, which is critical for OC
development, was impaired in cells expressing SH2(N+C). Arrest in OC differentiation was
evidenced by a reduction of p38 and Iκ-Bα phosphorylation as well as decreased NFATc1 and
cFos/cJun levels. Consistent with our hypothesis, SH2(N+C) abrogated formation of the
RANK/Gab2 complex which mediates NF-κB and AP-1 activation following RANK ligand
(RANKL) stimulation. Furthermore, the ability of SH2(N+C) to prevent inflammatory
osteolysis was examined in vivo following RANKL or LPS injections over the calvaria. Both
models induced osteolysis in the control group, whereas the SH2(N+C)-treated cohort was
largely protected from bone erosion. Collectively, these data indicate that inflammatory
osteolysis can be abrogated by treatment with a molecule composed of the tandem SH2 domains
of PLC β.
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2.3 Introduction
Pathological bone loss is a debilitating complication associated with prosthetic implants,
osteoarthritis, rheumatoid arthritis, and periodontal disease (1) and results from an increase in the
number and/or function of the bone-resorbing OC (2). OCs are differentiated from BMM
precursors in the presence of RANKL and macrophage colony-stimulating factor (M-CSF),
which bind RANK and c-Fms, respectively (3). Pro-inflammatory cytokines TNF-α, IL-1 , and
IL-6, which are produced at inflamed joints, further promote OCG and resorptive activity (4).
Such crosstalk between immune cells and OCs highlights the need for a therapeutic treatment
capable of reducing inflammation and preventing bone erosion.
PLC1 and 2 molecules are critical regulators of innate and adaptive immune
responses and are activated during OC differentiation. These enzymes convert
phosphatidylinositol 4,5 bisphosphate (PIP2) into two second messengers, inositol 1,4,5triphosphate (IP3) and diacylglycerol (DAG), leading to activation of IP3/calcium and DAGdependent pathways downstream of RANK, integrins, and a variety of immune receptors (5). For
example, in vitro studies of T lymphocytes demonstrate that PLC 1 is a critical modulator of T
cell receptor responses (6-8). However, PLC 1 is ubiquitously expressed, and its global deletion
leads to early embryonic lethality in the mouse (9). Thus, an approach to inhibit PLC 1 function
is likely to have broad off-target effects. PLC β expression is confined to cells of hematopoietic
lineage, including B lymphocytes, natural killer cells, mast cells, neutrophils, dendritic cells, and
OCs (10-14). Plc β-/- mice have increased bone mass (osteopetrosis) due to reduced
differentiation of BMMs into OCs (15). Additionally, Plc β-/- mice are protected from serumtransfer induced arthritis and antigen-induced arthritis due to functional defects in neutrophils
and dendritic cells, respectively (13,14). Therefore, PLC2 is a promising target for therapeutic
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design in the context of inflammatory osteolysis. However, due to its high homology with the
more ubiquitously expressed PLC 1, it is necessary to find inhibitors which can selectively block
PLC β activation.
PLC 1 and PLC β are unique from other PLC molecules because they contain
two tandem SH2 and an SH3 adaptor motifs. Initial studies suggested that these adaptor motifs
harbor an intrinsic regulatory function of the protein’s catalytic activity (16), exposing the
catalytic domain upon PLC 1/β phosphorylation (17). However, it is now established that these
SH2 and SH3 motifs can also mediate protein-protein binding via homodomain interactions (17).
Considering that the catalytic domains of PLC 1 and PLC β are over 90% homologous, while
their adaptor motifs are less than 60% homologous, the latter regions are a potential target for
specific inhibition.
The scaffolding function of PLC β, in addition to its catalytic activity, is required
for OC formation. Cells with a point mutation in the SHβ domain of PLC β are incapable of in
vitro OCG despite intact catalytic function (18). Thus, we hypothesized that the scaffolding
function of endogenous PLC β could be disrupted through a dominant negative effect by a
molecule encompassing the adaptor domains of PLC β. We report that a molecule composed of
the tandem SH2 motifs of PLC2 is able to abrogate OCG in vitro and in vivo by disrupting
protein interactions between RANK and Gab2. This approach may represent a novel method of
targeting PLC2 to prevent inflammatory bone loss.
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2.4 Materials and Methods
Plasmids and retrovirus generation
The SHβ or SHγ domains of PLC β were cloned into the blasticidin-resistant pMX retroviral
vector and fused with HA. To generate retrovirus, PLAT-E cells were transfected with
expression vector by using a TransIT transfection reagent (Mirus Bio). Viral supernatants were
collected on day 2 and day 3 post-transfection and immediately used to transduce freshly isolated
BMMs. After β4 h, medium containing 1 μg/ml blasticidin was added to cells for 48 h to select
for expressing cells.
Primary cell culture
Bone marrow was isolated from long bones of 6- to 8-week-old C57BL/6 mice and cultured in
alpha-MEM containing 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin, and 100
μg/ml streptomycin, and glutamine (α-10 medium), with 1/10 vol CMG14-12 cell-conditioned
medium as a source of macrophage colony-stimulating factor (M-CSF) (19) to obtain BMMs.
To form OCs, BMMs were cultured in α-10 medium with 100 ng/mL glutathione S-transferase–
receptor activator of NF-κB ligand (GST-RANKL) and 1/100 vol CMG14-12 for 5 days. Cells
were fixed in 4% paraformaldehyde and stained for tartrate-resistant acid phosphatase (TRAP)
using a commercial kit (Sigma 387-A).
Real-time PCR
BMMs were cultured with 100 ng/mL RANKL and 1/100 vol CMG14-12 for 0, 2, or 4 days.
Adherent cells were harvested in Trizol. Total RNA was isolated by chloroform extraction
followed by purification with the RNeasy Mini Kit (Qiagen). 1 μg of total RNA was reverse
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transcribed to cDNA using SuperScript II according to the manufacturer’s instructions
(Invitrogen). For real-time PCR, SYBR Green PCR Master Mix (Applied Biosystems) and
primers specific for murine NFATc1, TRAP, cathepsin K, calcitonin receptor, and GAPDH,
were used as follows: NFATc1, 5′-CCCGTCACATTCTGGTCCAT-γ′ and 5′CAAGTAACCGTGTAGCTGCACAA-γ′; TRAP, 5′-CAGCTCCCTAGAAGATGGATTCAT-γ′
and 5′-GTCAGGAGTGGGAGCCATATG-γ′; cathepsin K, 5′ATGTGGGTGTTCAAGTTTCTGC-γ′ and 5′-CCACAAGATTCTGGGGACTC-γ′; calcitonin
receptor, 5′-CAAGAACCTTAGCTGCCAGAG-γ′ and 5′-CAAGCACGCGGACAATGTTG-γ′;
GAPDH 5′-TGTGTCCGTCGTGGATCTGA-γ′and 5′-CCTGCTTCACCACCTTCTTGA -γ′).
Ct values were normalized to GAPDH internal control. Data are expressed as the relative fold
change compared to the expression in BMMs transduced with pMX empty vector control at day
0.
Bone Resorption
Analysis of bone resorption was completed as described previously (18). Briefly, BMMs were
plated on bovine bone slices and cultured with 1/100 CMG14-12 and 100 ng/ml GST-RANKL
for 10 days. Fresh medium was added every 2 days. Cells were removed from the bone surface
by using mechanical force and β N NaOH. Bone slices were stained with β0 μg/ml peroxidaseconjugated wheat germ agglutinin for γ0 min (Sigma) followed by γ,γ′-diaminobenzidine (0.52
mg/ml in PBS containing 0.1% H2O2) for 15 min. Bone resorption pits were visualized with a
light microscope and quantified using Image J software (NIH; http://rsbweb.nih.gov/ij).
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Immunoprecipitation
Cells were harvested in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM
EDTA, 10% glycerol) supplemented with protease inhibitors, and clarified by centrifugation.
The protein concentration of each sample was determined using bicinchoninic acid protein assay
(Biorad) and 1 mg of protein from each sample was used for IP. Samples were incubated with
anti-PLC β (Santa Cruz Biotechnology) or anti-Gab2 antibody (Millipore) overnight at 4°C and
with protein G agarose beads (Amersham) for 3 h at 4°C. Beads were washed three times in lysis
buffer and immunoprecipitates were used for western blotting.
RANKL, M-CSF, and vitronectin stimulation
For RANKL and M-CSF stimulation, pre-OCs were starved for 4 hours in α-MEM containing
2% FBS and then stimulated with RANKL (100 ng/ml) or M-CSF (100 ng/ml) in α-MEM for the
indicated times. Cells were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer
supplemented with HALT protease and phosphatase inhibitor cocktail (Pierce). To obtain nuclear
extracts from RANKL-treated cells, tissue-culture plates were washed with H2O and the
adherent cells were lysed with hypotonic buffer (10 mM HEPES, 1.5 mM MgCl2, 1 mM KCl, 1
mM DTT, and protease and phosphatase inhibitors), followed by addition of 0.1% NP40. After
centrifugation, the supernatants were collected (cytosolic fraction), while the pellets (nuclear
fraction) were suspended in high-salt buffer (hypotonic buffer plus 400 mM NaCl). For
vitronectin stimulation, pre-OCs were washed with PBS and lifted with 10% trypsin/EDTA in
PBS. Cells were replated on tissue-culture plates coated with vitronectin for the indicated length
of time and lysed in RIPA lysis buffer supplemented HALT protease and phosphatase inhibitor
cocktail.
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Western blot analysis and antibodies
The protein concentration of cell lysates or nuclear extracts was determined using bicinchoninic
acid protein assay (Biorad). An equivalent amount of protein for each sample was mixed with 5x
loading buffer (312.5mM Tris pH 6.8, 10% SDS, 50% glycerol, 0.05% bromophenol blue, 10%
-mercaptoethanol), separated by SDS-PAGE and transferred to PVDF membranes. Membranes
were probed with antibodies as indicated. Antibodies specific to the phosphorylated forms of
PLC 1, PLC β, ERK, JNK, c-Jun, IκBα, and Src (Y416) were purchased from Cell Signaling
Technology. Antibodies against p65, NFATc1, PLC β, TRAF6, RANK, Lamin B, and Sp1 were
purchased from Santa Cruz Biotechnology. The monoclonal antibody against -actin was
purchased from Sigma-Aldrich. Polyclonal Gab2 Ab was purchased from Millipore.
In vivo osteolysis models
WT C57Bl/6 mice were treated with 100 μg of RANKL and 107 PFU of adenovirus containing
LacZ (Ad-LacZ control) or SH2(N+C) (Ad-SH2(N+C)) by subcutaneous injections over the
calvaria daily for 5 days. Mice were sacrificed on day 6 and the calvaria were collected for
histological analysis. The calvaria were preserved in 10% buffered formalin overnight 24 h and
decalcified with 14% EDTA for 4 days. Paraffin-embedded sections were stained for tartrateresistant acid phosphatase (TRAP) to visualize OCs. WT C57Bl/6 mice were treated with γ0 μg
LPS and 107 PFU of adenovirus containing Ad-LacZ or Ad-SH2(N+C) by subcutaneous
injections over the calvaria at day 0, followed by 107 PFU of Ad-LacZ or Ad-SH2(N+C) on day
1, 3, and 5. Mice were sacrificed on day 6, and the calvaria were processed for histological
analysis as described above. Paraffin-embedded sections were stained for TRAP to visualize
OCs (Sigma).
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All mice used in these experiments were housed in the animal care unit of Washington
University School of Medicine, where they were maintained according to guidelines of the
Association for Assessment and Accreditation of Laboratory Animal Care. All animal
experimentation was approved by the Animal Studies Committee of Washington University
School of Medicine.
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2.5 Results
SH2(N+C) blocks OCG in vitro
To design an efficient strategy to specifically oppose endogenous PLC β activity in the
context of pathological bone loss, we focused on the protein modular domains, as the catalytic
motif is highly homologous to PLC1. Retroviral constructs harboring the N- and C-terminal
SH2 domains alone or in combination (N+C), the SH3 domain, or encompassing both SH2 and
SH3 regions were generated (Figure 2.1 A). These constructs were transduced into WT BMMs
that also express endogenous PLC β. Expression of the indicated domains was confirmed by
western blot (Figure 2.1 B). BMMs were treated with RANKL and M-CSF, and differentiation
to mature OCs was evaluated by TRAP staining. RANKL and M-CSF induced differentiation of
precursor cells into OCs in all groups, except in the presence of the SH2(N+C) and partially in
SH2(N+C)+SH3 expressing cells. Ectopic expression of SH2(N+C) significantly impaired OC
development (# of TRAP+ cells in SH2(N+C), 1.3±0.88 versus empty vector, 153.3±8.99, p <
0.0001). A 52% inhibition of OCG was observed in WT cells expressing SH2(N+C)+SH3,
while the differentiation of cells expressing a single SH2 (either SH2-N or SH2-C) or the SH3
motif alone was similar to cells infected with the empty vector (pMX; Figure 2.1 C-D).
Consistent with its inhibitory effect on OC formation, BMMs that were transduced with
SH2(N+C) and grown on cow bone slices in the presence of RANKL and M-CSF for 7 days,
formed fewer resorptive pits compared to pMX-transduced controls (Figure 2.2).
To further understand which stage of OC differentiation was blocked by the expression of
SH2(N+C), real time PCR was used to quantify expression of the early osteoclastogenic marker
TRAP and the master transcription regulator of OCG NFATc1, the functional OC protease
cathepsin K, and the calcitonin receptor expressed by mature OCs (Figure 2.3). WT cells
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transduced with empty vector alone showed an upregulation for all conventional markers of
OCG during four days of culture in the presence of RANKL and M-CSF. In contrast, expression
of OC differentiation markers was dramatically reduced in WT cells expressing SH2(N+C),
indicating that this molecule targets signaling pathways involved early in the OC differentiation
process.
RANK signaling cascade is inhibited by SH2(N+C) in vitro
In order to understand how SH2(N+C) inhibits OCG in vitro, we analyzed activation of
signaling pathways downstream of RANK/RANKL stimulation, M-CSF/c-Fms stimulation, or
vitronectin/alpha-v beta-γ (αV γ) integrin ligation. WT day β pre-OCs expressing SH2(N+C) or
vector control were stimulated with 100ng/ml RANKL for 0 to 60 minutes, as indicated. PreOCs expressing SH2(N+C) failed to activate downstream RANK signals, as assayed by Western
blot for phosphorylation of PLCβ, IKBα and pγ8 and upregulation of cFos and NFATc1 (Figure
4A). Activation of JNK was unaffected (not shown). Furthermore, nuclear translocation of
NFATc1 and phosphorylated c-Jun was inhibited by SH2(N+C) expression (Figure 4B). In
contrast, when pre-OCs were stimulated with 100ng/ml of M-CSF over the indicated time
course, cells expressing SH2(N+C) induced phosphorylation of the downstream molecules AKT
and ERK equivalent to cells expressing the vector alone (Figure 2.4 C). Phosphorylation of
Pyk2, c-Src, and IkB was decreased in SH2(N+C)-expressing pre-OCs plated on vitronectin
(Figure 4D). All together, these results indicate that SH2(N+C) primarily inhibits the RANKLand integrin-mediated signaling pathways which are integral to OC differentiation.
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SH2(N+C) blocks association of Gab2 with PLC2 and RANK
In order to understand the mechanism by which SH2(N+C) interferes with the RANKL
signaling cascade, a co-immunopreciptation assay of cell lysates from RANKL-stimulated preOCs was preformed. Following RANKL binding to its receptor RANK, the signaling adaptor
Gabβ is recruited to the RANK complex (β0). Gabβ associates with PLC β to stimulate
phosphorylation of Iκ-Bα leading to OCG (15,20). SH2(N+C) dampened the association of
PLC β with Gabβ compared to pre-OC expressing vector only (Figure 2.5 A). Furthermore,
SH2(N+C) also impaired the association of RANK with Gab2 but did not effect recruitment of
TRAF6 to Gab2 (Figure 2.5 B). Thus, SH2(N+C) inhibits RANK signaling cascades by
impeding protein scaffolding at the receptor.
SH2(N+C)blocks OC formation in vivo
Finally, the potential efficacy of targeting PLC2 adaptor motifs to inhibit bone erosion
was examined in vivo, using two established models of OCG. To facilitate these studies,
adenoviral vectors were generated to express SH2(N+C) or beta galactosidase (LacZ) as a
control. LacZ expression after one intra-articular injection of 107 PFU was confirmed by X-gal
staining (data not shown). In the first model, 100 μg of RANKL and 107 PFU of Ad-SH2(N+C)
or Ad-LacZ were administered to WT mice by subcutaneous injections over the calvaria daily for
5 days. Mice were sacrificed on day 6, and calvaria were prepared for histological examination
to assess the number of TRAP+ OCs. WT mice receiving SH2(N+C) adenovirus displayed
significantly fewer OCs compared to LacZ-expressing controls (Figure 2.6 A). Furthermore, the
effect of SH2(N+C) in the context of inflammatory bone loss was examined using an established
model of OCG initiated by a single LPS injection over the calvaria. γ0 μg of LPS and 107 PFU
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of SH2(N+C) or control LacZ adenovirus were injected over the calvaria at day 0, followed by
107 PFU of SH2(N+C) or control LacZ adenovirus every other day for five days. Mice were
sacrificed on day 6, and calvaria were examined by histology. WT mice receiving SH2(N+C)
adenovirus developed half the number of TRAP-positive OC compared to LacZ-expressing
controls (Figure 6B). These results indicate that PLC2 can be specifically targeted in vivo by a
dominant-negative effect of the SH2(N+C), and that this approach can abrogate inflammatoryinduced OC formation.
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2.6 Discussion
Inhibitors that block the catalytic activity of PLC proteins, such as ET-18-OCH3 and
U73122, have been used to establish the function of PLCs and the importance of PIP2 hydrolysis
into IP3 and DAG in various cellular contexts. However, the major limitation of these inhibitors
is lack of specificity. Using a genetic model consisting of Plc β-deficient mice, we previously
showed that PLC β is required for the maintenance of basal bone mass and for protection from
inflammatory arthritis (13-15). Thus, the goal of the current study was to identify a specific
approach to target endogenous PLC β function. We report that ectopic expression of the tandem
SHβ domains of PLC β phenocopies the intrinsic OC deficit of Plc β-/- mice (15) by disrupting
the protein association between RANK and Gab2. This approach is a novel method of targeting
endogenous PLC 2 function to negate pathological bone loss.
PLC β is important for both OC differentiation and bone resorption. We previously
proposed that in the context of OCG, PLC2 serves a dual purpose as both an active lipase,
leading to expression of the master osteoclastogenic transcription factor NFATc1, and as a
critical scaffolding molecule facilitating NF-κB and AP-1 induction. Point mutations in the SH2
domains of PLC β (R564K/R67βK) render BMMs unable to differentiate to OCs, despite intact
catalytic activity (18). Here, we show that the overall effect of the SH2(N+C) was inhibition of
the RANK signaling cascade and suppression of OCG. Our observations support an independent
scaffolding function of PLC β in which the SHβ motifs of PLC β mediate the association
between RANK and Gab2. Our results suggest that ectopic expression of SH2(N+C) exerts a
dominant negative effect on formation of this complex by sequestering Gab2 and thus impairing
its binding to the receptor RANK. These observations are consistent with modeling of
intracellular RANK receptor interactions (21,22). During the first hour of RANKL stimulation
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(early activation phase), PLC β is recruited to RANK, and Gab2 binds weakly to the recruited
PLC β without interacting directly with RANK (β1). Following prolonged RANKL stimulation
(beyond 24 h) Gab2 may bind to the HCR region of RANK and recruit TRAF6 (21,22). Thus, it
is hypothesized that the scaffolding function of PLC β is critical in the early phase, whereas its
catalytic activity may modulate signaling during the early and late phases of RANKL stimulation
(21,22). Importantly, concurrent exposure to the SH2(N+C) and RANKL can limit OCG in vitro
and in vivo.
Gab2 belongs to a family of adaptor molecules that mediate signals downstream of a
diverse set of receptors for molecules such as growth factors, antigens, cytokines, TLR agonists,
and the RANK receptor. Gab2-deficient mice exhibit impaired OCG and a net increase in bone
mass. Gab2 is also necessary for the differentiation of human progenitor cells into OCs (20). In
vitro, BMMs from Gab2-deficient mice do not form mature OCs due to an inherent defect that
correlates with reduced RANKL-mediated activation of NF-kB, Akt, and JNK. Similarly, ectopic
expression of SH2 (N+C) primarily affects RANKL signaling in OCs, without altering
downstream signals from the MCSF receptor, thus implying a good level of specificity for this
type of targeted approach. Since a Gabβ/PLC β complex is likely to form in response to various
stimuli, inhibitory effects of the SH2(N+C) in other contexts are possible and warrant further
investigation.
In contrast to the SH2(N+C), the anti-osteoclastic effects of molecules encompassing
each single SHβ domain or the entire adaptor motif of PLC β, consisting of the two SHβ
domains along with the SH3 motif, were very minimal. It is likely that targeting only one SH2
domain is not sufficient to sequester adaptor molecules from forming a complex with RANK.
However, it was surprising to find that a larger fragment encompassing the entire adaptor region
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of PLC β had less effect than the SHβ(N+C) molecule. Initial models of PLC 1, and perhaps
PLC β, function suggested that, at the 3D structural level, the entire adaptor region
(SH2(N+C)+SH3) forms a cap that regulates exposure of the catalytic domain to its substrate
(17). Indeed, overexpression of SH2(N+C)+SH3 was shown to block phospholipase activity of
cell lysates in vitro (16). Similarly, this region exerted a dominant-negative effect to reduce
PLC 1 enzyme activity in prostate tumor cells and resulted in reduced tumor invasiveness (βγ).
While previous reports clearly demonstrate that the entire adaptor region modulates catalytic
activity, they do not clarify whether or not this region also mediates protein-protein binding. In
the OCs, the incomplete inhibition of OCG by SH2(N+C)+SH3 supports the hypothesis that
SHβ(N+C)+SHγ is not fully capable of blocking PLC β catalytic activity.
SH2(N+C) anti-osteoclastogenic effects are also observed in vivo using two
models of bone loss, consisting of RANKL or LPS supracalvarial injections. While RANKL
directly stimulates the differentiation of monocytes into OCs, LPS-induced bone loss is
secondary to immune activation. In vivo immune phenotypes caused by genetic alterations of
Plc β have been described. We and others have shown that PLC β regulates inflammation and
autoimmunity, specifically within the bone microenvironment. Plc β-/- mice are protected from
immune activation in serum-transfer arthritis and antigen-induced arthritis (13,14). In humans, a
dominantly-inherited disease called PLAID (PLC β-associated antibody deficiency and immune
dysregulation) is caused by mutant alleles of PLC β in which small, in-frame genomic deletions
eliminate part or all of the C-terminal SHβ domain of PLC β. Immune cells from these patients
displayed functional deregulation, with increased activation in response to some stimuli and
decreased activation in other circumstances (12). Although we did not directly test the effects of
SH2(N+C) on immune cell activation or function, it is possible that SH2(N+C) may also
58

modulate inflammatory responses involved in LPS-mediated bone loss in addition to directly
targeting the OCs. Further studies are needed to examine potential anti-inflammatory effects of
SHβ(N+C). In conclusion, the results reported here provide strong evidence that PLC β adaptor
function can be targeted in vitro and in vivo to suppress OCG and bone erosion.
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2.8 Figure Legends
FIGURE 2.1. SH2(N+C) blocks OC formation in vitro.
A, Schematic representation of the functional domains of the PLC β protein and the regions of
the protein present in retrovirus constructs. B, Western blot analysis was used to confirm
expression of the indicated domains of PLC β by detection of the HA tag. C-D, WT BMMs
were transduced with retrovirus to express the indicated peptides and cultured under
osteoclastogenic conditions. Cells were fixed and stained to detect TRAP+ cells. C,
Quantification of the TRAP+ cells per well. D, Representative bright-field micrographs.
FIGURE 2.2 SH2(N+C) blocks bone resorption.
WT BMMs were transduced with pMX empty vector or -SH2(N+C) and cultured on tissue
culture plastic, A, or cow bone slices, B, in the presence of 100 ng/mL RANKL and 10 ng/mL
M-CSF. A, Representative images of cells stained with TRAP. B, Representative images of
cow bone slices stained with wheat germ agglutinin to visualize areas of resorbed bone. C, The
surface area of resorbed bone was quantified as percent of total bone surface area.
FIGURE 2.3. SH2(N+C) regulates the expression of osteoclastogenic genes.
WT BMMs expressing pMX empty vector control or SH2(N+C) were cultured in the presence of
100 ng/mL RANKL and 10 ng/mL M-CSF. Relative expression of the OC-specific markers
TRAP, cathepsin K (CatK), calcitonin receptor (CTR), and NFATc1 were detected by real-time
PCR. Ct values were normalized to GAPDH and are represented as fold change compared to
pMX control at day 0.
FIGURE 2.4. SH2(N+C) suppresses RANK signaling.
WT BMMs were transduced with pMX empty vector or SH2(N+C) in the presence of 100
ng/mL RANKL and 10 ng/mL M-CSF prior to starvation and stimulation. A-B, Pre-OCs were
stimulated with 100 ng/mL RANKL for 0 – 60 minutes, as indicated. Whole cell lysates (A) and
nuclear extracts (B) were separated by SDS-PAGE and western blots were probed with the
indicated antibodies. Total Pyk2, actin, or Lamin B are shown as loading controls. C, Pre-OCs
were stimulated with 50 ng/mL M-CSF for 0 – 30 minutes, as indicated, and analyzed as in A.
D, Pre-OCs were lifted and replated on plates coated with vitronectin for 0 – 60 minutes, as
indicated, and analyzed as in A.
FIGURE 2.5. SH2(N+C) disrupts binding of Gab2 with PLC2 and RANK.
WT BMMs were transduced with pMX empty vector or SH2(N+C) and cultured in the presence
of 100 ng/mL RANKL and 10 ng/mL M-CSF prior to starvation and stimulation. Pre-OCs were
stimulated with 100 ng/mL RANKL for 0 – 60 minutes, as indicated. 1 mg of protein from
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whole cell lysates were immunoprecipitated with anti-PLC β, A, or anti-Gab2 antibody, B, and
then separated by SDS-PAGE. Western blots were probed with antibodies as indicated.
FIGURE 2.6. SH2(N+C) inhibits OC formation in vivo.
A, WT C57Bl/6 mice were treated with 100 μg RANKL and 107 PFU of Ad-LacZ or AdSH2(N+C) by supracalvarial injection daily for 5 days. Mice were sacrificed on day 6 and the
calvaria were collected for histological analysis. Representative images of histological sections
stained to detect TRAP+ OCs (red cells) and quantification of the percent quantification of OC
surface per bone surface (Oc.S./B.S.) and OC number per bone surface (Oc.N./B.S.). B, WT
C57Bl/6 mice were treated with γ0 μg LPS and 107 PFU of Ad-LacZ or Ad-SH2(N+C) by
supracalvarial injection at day 0 followed by Ad-LacZ or Ad-SH2(N+C) every other day. Mice
were sacrificed on day 6 and the calvaria were collected for histological analysis. Representative
images of histological sections stained to detect TRAP+ OCs and quantification of OC surface
per bone surface (Oc.S./B.S.) and OC number per bone surface (Oc.N./B.S.) are shown.
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Chapter 3. The Role of Tmem178 in the Regulation of Osteoclastogenesis
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3.2 Abstract
PLC2-dependent calcium (Ca2+) oscillations are indispensable for NFATc1 activation
and downstream gene transcription driving osteoclastogenesis during skeletal remodeling and
pathological bone loss. Here we describe the first known function of transmembrane protein 178
(Tmem178), a PLC2 downstream target gene, as a critical modulator of the Ca2+-NFATc1 axis.
In surprising contrast to the osteopetrotic phenotype of PLC2-/- mice, Tmem178-/- mice are
osteopenic in basal conditions and are more susceptible to inflammatory bone loss, owing to
enhanced osteoclast formation. Mechanistically, Tmem178 localizes to the ER membrane and
restrains ER Ca2+ release, thus controlling NFATc1 induction. Importantly, downregulation of
Tmem178 is observed in human CD14+ monocytes exposed to plasma from systemic juvenile
idiopathic arthritis patients. Similarly to the mouse model, reduced Tmem178 expression in
human cells correlates with excessive osteoclastogenesis. In sum, these findings identify an
essential role for Tmem178 to maintain skeletal mass and limit pathological bone loss.
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3.3 Introduction
In recent years, the skeleton has been appreciated as a dynamic system which, in addition
to serving its evident mechanical functions, impacts whole-body metabolism. The bone is a
reservoir for mineral stores, namely calcium (Ca2+) and phosphate, and also releases and
responds to numerous growth factors and hormones. Through these pathways, skeletal turnover
stimulates cross-talk with the nervous, endocrine, immune, reproductive, and digestive systems.
Skeletal fragility is observed in inflammatory, endocrine, and metabolic disorders [1, 2]. Perhaps
the most studied inflammatory condition associated with dysregulated bone homeostasis is
rheumatoid arthritis (RA). Elevated levels of inflammatory cytokines acting in concert with the
receptor activator of NF-kB ligand (RANKL) drive excessive osteoclast (OC) differentiation and
lead to local joint erosion as well as systemic bone loss [3, 4]. Pathological bone loss was also
observed in up to 50% of patients with systemic juvenile idiopathic arthritis (sJIA) before the
pre-biological era. However, even in the face of optimal anti-inflammatory therapy, joint damage
is still observed in up to 20% of children without active systemic features (Janow et al.,
manuscript submitted). Furthermore, low bone mass and high risk of fragility fracture are often
seen in adults who suffered from sJIA during childhood [5]. Unfortunately, at the moment there
are no biomarkers of specific factors that would help identify which subset of patients will
develop active erosive disease or long term osteopenia.
Ca2+ is a ubiquitous signaling messenger directing diverse processes such as
differentiation, proliferation, migration, and gene transcription. Ca2+ fluxes are particularly
important during the OC differentiation process as a rise in cytoplasmic Ca2+ triggers the
Ca2+/calmodulin-dependent nuclear translocation of NFATc1, a master transcription factor for
osteoclastogenesis [6-8]. Ca2+ signaling is initiated by binding of RANKL to its receptor RANK
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inducing the activation of PLC2-mediated release of ER Ca2+ stores through IP3 receptors
(IP3R). Upon detecting depletion of ER Ca2+, Stim1, an ER Ca2+ sensor, binds to Orai1, a poreforming unit of the CRAC (Ca2+ release activated Ca2+) channel, and allows extracellular Ca2+
entry through the plasma membrane [9-19]. Ca2+ entry from the extracellular milieu in the OC
can also occur via transient receptor potential V channels [20-22]. ER Ca2+ is re-filled by the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) [23]. Genetic or pharmacological
interference of Ca2+ channel activity, as well as blockade of PLC2-mediated Ca2+ release,
impedes osteoclastogenesis, cell motility, and bone resorption in vitro and in vivo [24-29].
Because of its importance to many cellular responses, Ca2+ mobilization is finely
controlled by regulatory proteins that potentiate or suppress Ca2+ transport and dictate amplitude,
duration, and/or frequency of Ca2+ fluxes. Several interacting partners of Stim1 and Orai1 have
been identified as regulators of CRAC channel activity. Interestingly, emerging data also indicate
that Stim1 and Orai1 can interact with regulatory proteins to exert non-CRAC channel-related
functions [30, 31]. Such interacting proteins remain unknown in the context of the OC.
In this study we identify for the first time a previously uncharacterized protein, Tmem178, as a
novel modulator of ER Ca2+ mobilization in OCs. Our data demonstrate that Tmem178 is a
negative regulator of OC differentiation by limiting ER Ca2+ release and activation of the Ca2+dependent osteoclastogenic transcription factor NFATc1. In mice, Tmem178 deficiency leads to
a significant osteopenic bone phenotype owing to increased OC numbers. Human monocytes
treated with plasma from sJIA patients downregulate Tmem178 and undergo more robust
osteoclastogenesis, suggesting that Tmem178 may be a modulator of disease-associated bone
erosion.
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3.4 Materials and Methods
Mice
PLC2-/- mice were kindly provided by Dr. JN Ihle (St. Jude Children’s Research Hospital,
Memphis, Tennessee, USA). Tmem178-/- mice (Strain B6;129S5-Tmem178tm1Lex/Mmucd)
were generated by the trans-NIH Knock-Out Mouse Project (KOMP) and purchased from the
KOMP Repository at UC Davis (www.komp.org) (stock number 032664-UCD). Tmem178 bone
phenotyping was performed with mice of the C57Bl/6-129 background maintained by
heterozygous breeding. In vitro osteoclast experiments were performed with bone marrow from
both mice of C57Bl/6-129 and C57Bl/6 background. All experiments were approved by the
Washington University School of Medicine animal care and use committee.
Histology and µCT
Microcomputed tomography and histological analysis were performed as previously
described [53].For histology to detect OCs, bones were preserved in 10% buffered formalin
overnight and decalcified using 14% EDTA, pH 7.0, for 10 days (long bones) or 3 days
(calvaria) with gentle rocking and daily replacement of solution. Decalcified bones were then
dehydrated in graded alcohol, cleared through xylene, and embedded in paraffin. Paraffin blocks
were sectioned longitudinally. Five-micron sections were then stained with TRAP (Sigma) to
detect OCs and counterstained with hematoxylin. For double-labeling, 4 week-old WT and
Tmem178-/- mice were injected with calcein and alizarin red at a 4 day interval. Calvaria were
harvested on day 5, stored in 70% ethanol and protected from light. Five-micron sections were
analyzed from non- decalcified, methacrylamide embedded calvaria. Sections were analyzed
with a Nikon Eclipse 80i microscope and a 10X objective. For μCT, 3D images from intact
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mouse femurs or calvaria were obtained on a μCT40 scanner (Scanco Medical). For LPSinduced osteolysis on the calvaria, resorbed area was quantified using Image J Software.
Inflammatory osteolysis models
For serum-transfer arthritis, 200 l of serum from K/BxN mice was injected i.p. into recipient
mice on day 0, day 2 and day 6. 50 g of Lipopolysaccharides (LPS) from Escherichia coli
0111:B4 (Sigma) was injected on day 6. Mice were sacrificed on day 14, and long bones were
harvested for analysis by CT and histology. For surpacalvarial LPS, 100 g LPS was injected
subcutaneously over the calvaria on day 0. Mice were sacrificed on day 5, and calvaria were
harvested for analysis by CT and histology.
Primary cell culture
BMMs were isolated from 6-8 week old mice as previously described [54]. Briefly, the marrow
of long bones was flushed by centrifugation and isolated cells were grown in alpha medium
(Sigma) in the presence of 100 ng/ml M-CSF for 3 days. To form OCs, BMMs were cultured
with 50 ng/ml glutathione-S-transferase (GST)-RANKL and 10 ng/ml M-CSF for 3-5 days. Cells
were fixed in 4% paraformaldehyde (Polysciences) and stained for TRAP using the leukocyte
acid phosphatase kit (Sigma).
Bone resorption
5 × 104 BMMs or preOCs were cultured on bovine bone slices the presence of 10ng/ml M-CSF
and 50ng/ml GST-RANKL. Cells were then removed from the bone surface using sodium
hydroxide and gentle agitation, and bone slices were stained with 20 µg/ml peroxidaseconjugated wheat-germ agglutinin (Sigma) for 30 min at room temperature, followed by
incubation with 3,3'-diaminobenzidine (0.52 mg/ml in PBS containing 0.1% H2O2) for 30 min.
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Bone resorption pits were analyzed using a light microscope (Nikon) and quantified using Image
J software.
Western blot and antibodies
For RANKL and M-CSF signaling assays, BMMs were starved overnight in cytokineand serum-free alpha medium; preOCs were starved for 4 hours in cytokine-free alpha medium
containing 2% FBS. For total cell lysates, BMMs or preOCs were lysed in RIPA buffer
supplemented with protease/phosphatase inhibitor cocktail (Pierce). For nuclear extracts, cells
lysed with hypotonic buffer (10 mM HEPES, 1.5 mM MgCl2, 1 mM KCl, 1 mM DTT, and
protease and phosphatase inhibitors), followed by addition of 0.1% NP40. After centrifugation,
the supernatants were collected (cytosolic fraction), while the pellets (nuclear fraction) were
suspended in high-salt buffer (hypotonic buffer plus 400 mM NaCl). For immunoprecipitation,
cells were harvested in TNE lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM
EDTA, 10% glycerol). Protein concentration was determined by bicinchoninic acid protein assay
(Biorad), resolved by SDS-page and subjected to western blot analysis
For immunoblotting and immunoprecipitation, phospho-ERK (D13.14.4E), phospho-JNK
(81E11), phospho-p38 (3D7), phospho-IκBα (14D4), phospho-AKT (587F11), Myc (9B11),
Pyk2 (3292), and Lamin B1 (13435) antibodies were obtained from Cell Signaling Technology.
NFATc1 (7A6) was purchased from Santa Cruz, as well as secondary anti-mouse and anti-rabbit
HRP-conjugated antibodies. Mouse monoclonal HA.11 (16B12) was purchased from Covance.
Flag-M2 and beta-actin were purchased from Sigma. Protein A/G beads were obtained from
Santa Cruz.
Real-time PCR
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Cells were lysed in TRIzol (Invitrogen), and whole tissues were snap frozen in liquid nitrogen
then pulverized with a dismembrator (B. Braun Biotech International) in TRIzol. Total RNA was
isolated using the RNeasy Mini Kit (Qiagen) and reverse transcribed to cDNAs using EcoDry
Premix (Oligo dT) (Clontech). For quantitative real-time PCR, NFATc1 was amplified using 5′CCCGTCACATTCTGGTCCAT-3′ and 5′-CAAGTAACCGTGTAGCTGCACAA-3′.TRAP was
amplified using 5′-CAGCTCCCTAGAAGATGGATTCAT-3′ and 5′GTCAGGAGTGGGAGCCATATG-3′; cathepsin K using 5′ATGTGGGTGTTCAAGTTTCTGC-3′ and 5′-CCACAAGATTCTGGGGACTC-3′; calcitonin
receptor using 5′-CAAGAACCTTAGCTGCCAGAG-3′ and 5′CAAGCACGCGGACAATGTTG-3′; and cyclophilin using 5’AGCATACAGGTCCTGGCATC-3’ and 5’-TTCACCTTCCCAAAGACCAC-3’. Tmem178 in
mouse cells was amplified using 5’-ATGACAGGGATATTTTGCACCAT-3’ and 5’CCGGTTCAAGTCATAGGAGACACT-3’and in human cells using 5’ACTTATGCCGCCAGTATCTCG-3’ and 5’- AGGCGCAAAAGATGGACCAG-3’. For
measuring transcriptional repressors, Bcl 6 was detected using 5’-TTA GAG CCC ATA AGA
CAG TGC T-3’ and 5’-TCA GGT TGA GCC TAG ATG TGT-3’; IRF8 using 5’-AAG GTC
ACC GTG GTC CTT AG-3’ and 5’-GGA AAG CCT TAC CTG CTG AC-3’. SYBR green dye
was used for detection of the product using the SYBR Green PCR Master Mix assay (Applied
Biosystems). The standard curve used a series of duplicate dilutions of plasmid for each gene and
cyclophilin cDNA. The amplification reaction was performed for 40 cycles with denaturation at
95°C for 10 minutes, followed by annealing at 95°C for 15 seconds and extension and detection
at 60°C for 1 minute. The relative abundance of each target was calculated as 1000×2−(Ct target
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gene−Ct cyclophilin

), where Ct represents the threshold cycle for each transcript, and cyclophilin is the

reference.
Plasmids and retrovirus generation
Human Tmem178 cDNA (Clone ID 528607- Open Biosystems) was cloned into the blasticidinresistant pMX retroviral vector containing an HA tag at the C-terminus using BamHI and XhoI
restriction sites. Stim1-Myc and Orai1-Flag were a gift from Dr. Monika Vig (Washington
University).
To generate retrovirus, PLAT-E cells were transfected with expression vector using PolyJet
transfection reagent (SignaGen). Viral supernatants were collected on day 2 post-transfection and
immediately used to infect freshly isolated BMMs with the addition of 4 ug/ml polybrene. After
24 h, complete medium containing 1 μg/ml blasticidin was added to cells for 48 h to select for
expressing cells. Selected cells were differentiated to OC with 10 ng/ml M-CSF and 50 ng/ml
RANKL in the presence of 0.3 ug/ml blasticidin. For expression studies in HEK293T cells,
Tmem178-HA, Stim1-Myc-His, or Orai1-Flag were co-transfected into HEK293T cells using
PolyJet. Transfected cells were used for Ca2+ imaging or lysed for immunoprecipitation
experiments 24 hours later.
Immunofluorescence and microscopy
OCs were differentiated on glass coverslips with 10 ng/ml M-CSF and 50 ng/ml RANKL. Cells
were fixed with 4% paraformaldehyde (Polysciences) for 10 minutes then rinsed 3 times with
PBS. Cells were permeabilized with 0.2% Triton for 10 minutes, and blocked in 3% BSA-1%
FBS for 30 minutes. Primary antibody diluted in PBS supplemented with 3% BSA and 0.1%
saponin was added for 2 hours at room temperature, followed by 2 hours incubation with
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secondary antibody (1:500) together with phalloidin-Alexa Flour 488 (1:500) (Molecular
Probes). The following antibodies and dilutions were used: Calnexin (C20) purchased from
Santa Cruz (1:50), c-myc (9E10) from Santa Cruz (1:50), HA (HA-7) from Sigma (1:2000), HAFITC (Ab1208) purchased from Abcam (1:100), anti-goat Alexa Fluor 594 (1:500), anti-mouse
Alexa Fluor 594 (1:500), and anti-mouse Alexa Fluor 488 (1:100). Vectashield containing dapi
nuclear stain was purchased from Vector Labs. Slides were analyzed using a Nikon Eclipse 80i
microscope and a 63X Plan APO objective. Images were captured with a Nikon DS-Qi1MC
camera (Nikon). For confocal images, slides were analyzed using a Zeiss Axiovert 200M
microscope and Zeiss LSM 5 PASCAL system.
Single cell Ca2+ measurements
For Ca2+ measurements, cells were seeded in a black 96-well plate. BMMs were seeded at a
concentration of 12,000 cells/well for 1 day with 10 ng/ml M-CSF and 50 ng/ml RANKL. Cells
were loaded with 3 M Fura-2-AM (Invitrogen) in phenol red-free DMEM (Invitrogen)
containing 10 ng/ml M-CSF for 30 minutes at room temperature in the dark. Cells were washed
twice with HBSS and imaged immediately in phenol red-free DMEM containing 10 ng/ml MCSF. Cells were imaged for 1 minute before the addition of 100 ng/ml GST-RANKL. For preOC
treated with thapsigargin or ionomycin, cells were imaged in Ca2+-HBSS. For experiments using
HEK293T cells, 24 hours post-transfection cells were plated at a concentration of 15,000
cells/well for 4 hours on poly lysine-coated wells. Cells were loaded with 3

-2-AM in

HBSS for 30 minutes at 37°C. Cells were washed twice in HBSS and imaged immediately in
Ca2+-free HBSS. Fura-2 ratios were measured by alternate excitation at 340 nm and 380 nm. An
Olympus IX-71 inverted microscope with a Lamda-LS illuminator, Fura-2 (340/380) filter set, a
10X 0.3NA objective lens, and a Photometrics Coolsnap HQ2 CCD camera was used to capture
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images at a frequency of 1 image pair every 2 seconds. Data were acquired and analyzed using
MetaFluor. At least 40 cells per field were analyzed in each replicate.
Human plasma preparation
The study was approved by the Institutional Review Board at Stanford University. All subjects
provided informed consent before participating in the study in accordance with the Declaration
of Helsinki. Plasma was prepared from whole, anti-coagulated blood within 2 hours after blood
draw. Samples were centrifuged at 25°C at 514 g for 5 minutes to remove cells, and were
centrifuged for 2 additional rounds at 4°C at 1730 g for 5 minutes and 15 minutes to remove
platelets. Plasma samples were stored at -80°C until use.
Human osteoclastogenesis
PBMCs were isolated from healthy donor by Ficoll gradient centrifugation. CD14+ cells were
isolated by positive selection with anti-CD14 magnetic beads (Miltenyi Biotec). For
osteoclastogenesis, 600,000 CD14+ PBMCs were seeded in a 96-well plate with 30 ng/ml human
M-CSF. After 24 hours, media was added to a final concentration of 15 ng/ml human M-CSF
and 100 ng/ml GST-RANKL. At 48 hours and 96 hours, the total media was changed. The
complete media included 15 ng/ml hM-CSF, 100 ng/ml GST-RANKL, and 15% plasma by
volume (25 l in 200 l total volume). For Tmem178 mRNA analysis, CD14+ PBMCs were
cultured with hM-CSF and GST-RANKL for 48 hours. 15% control or patient plasma was added
for 8 hours.
Statistics
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All data represent mean ± SD. Data were analyzed using two-tailed Student’s t test, with
a P value of <0.05 set as statistically significant. *p<0.05 **p<0.01, ***p<0.001

83

3.5 Results
Tmem178 deletion decreases bone mass in basal conditions
We have previously reported that ablation of PLC2 results in a blockade of
osteoclastogenesis owing to defective NFATc1 induction in vitro and in vivo [32, 33]. PLC2 deficient mice are osteopetrotic and are also protected from inflammatory osteolysis [34, 35].
Because PLC2 shares significant homology with the more ubiquitously expressed isoform
PLC1, however, attempts at pharmacological inhibition of PLC2 are likely to have broad offtarget effects. Therefore, we sought to identify PLC2-dependent signaling mediators that could
specifically direct therapeutic design for disorders caused by OC overactivity such as
osteoporosis and rheumatoid arthritis. We performed a gene array comparing wild-type (WT)
and PLC2-deficient OC precursors to identify novel genes downstream of PLC2 signaling.
Transmembrane protein 178 (Tmem178) was highly expressed in WT cells, but Tmem178
expression was abrogated in cells lacking PLC2 (data not shown).
Tmem178 is a previously unstudied multi-pass integral membrane protein. Despite its
name, Tmem178 does not share any structural domains or homology with other “Tmem”
proteins. We began by assessing Tmem178 expression in whole tissues from WT and PLC2-/mice. Strikingly, we found that Tmem178 is highly expressed in WT whole bone, while
transcript levels are low in other tissues including, spleen, liver, thymus, and testes (Figure 3.1
A). Confirming the gene array data, Tmem178 expression was strongly dependent on PLC2.
Thus, we hypothesized that Tmem178 is a downstream target controlling PLC2’s effects on
bone homeostasis.
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To establish the physiological importance of Tmem178 we examined the bone phenotype
of Tmem178-null mice in basal conditions. We expected Tmem178-/- mice to mirror the
osteopetrotic phenotype of PLC2-/- mice. Surprisingly, 16 week-old female Tmem178-/- mice
display a 35% decrease in trabecular bone volume with significant trabecular thinning compared
to WT littermates (Figure 3.1 B-D). Tartrate-resistant acid phosphatase (TRAP) staining of long
bone sections reveals a significant increase in OC surface normalized to bone surface in
Tmem178-/- mice (Figure 3.1 E-F). Similarly, male Tmem178-/- mice show a 10% decrease in
BV/TV compared to WT controls, with concomitant increase in OC surface/bone surface (n = 45) (data not shown). Because OC-mediated bone resorption is coupled to OB activity, we
performed double labeling in 4 week-old mice by administering calcein and alizarin red at a 5
day interval. WT and Tmem178-/- mice show no significant differences in mineral apposition
rate (MAR) and bone formation rate (BFR) (Figure 3.1 G-I). Moreover, quantitative real time
PCR of whole bones flushed of marrow cells reveals equal expression of RANKL and OPG in
WT and Tmem178-/- mice (Figure 3.1 J-K). Thus, the basal osteopenic phenotype of Tmem178/- mice can be attributed to an OC-intrinsic effect. These in vivo data suggest that Tmem178 acts
to suppress OC differentiation via an unexpected negative feedback loop downstream of PLC2.
Tmem178 expression is controlled by NFATc1
To determine whether Tmem178 exerts cell autonomous effects in the OC lineage, we
measured its transcript levels during osteoclastogenesis in vitro. Tmem178 mRNA increases
during osteoclastogenesis and is dependent on PLC2 (Figure 3.2 A-B). A similar extent of
Tmem178 induction is observed in human CD14+ monocytes treated with RANKL compared to
cells cultured with M-CSF alone (Figure 3.2 C). In contrast to the OC, Tmem178 is not
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significantly expressed in the OB, confirming the observation that Tmem178 deletion does not
affect bone formation (Figure 3.2 A).
PLC2’s catalytic activity is required for induction of NFATc1 early in
osteoclastogenesis. To better understand how PLC2 controls Tmem178 expression, we utilized
NFATc1-deficient (NFATc1Δ/Δ) precursors in which conditional deletion of NFATc1 is mediated
by inducible Mx1-cre [36]. NFATc1fl/fl without Mx1-Cre served as control. Interestingly,
RANKL-induced Tmem178 upregulation is blunted in NFATc1Δ/Δ cells compared to controls
(Figure 3.2 D). These data position Tmem178 directly downstream of the RANKL-PLC2NFATc1 axis in the OC.
Tmem178 deletion enhances osteoclastogenesis
To determine the role of Tmem178 in the OC, we cultured bone marrow macrophages
(BMMs) with M-CSF and RANKL for 3-5 days. Tmem178-/- BMMs display accelerated
differentiation and increased OC numbers compared to WT (Figure 3.2 E-F). This rapid
formation of multi-nucleated polykaryons is paralleled by an earlier and greater magnitude of
induction of the early OC marker TRAP (Acp5), the functional protease Cathepsin K (CtsK), and
calcitonin receptor (Calcr), a marker of committed OCs (Figure 3.2 G). To determine if
Tmem178 affects OC resorptive activity, we cultured BMMs on bovine bone slices in the
presence of M-CSF and RANKL for 10 days. Resorptive pit area was significantly increased in
Tmem178-/- cultures compared to WT (Figure 3.2 H-I). Because enhanced resorption could be a
consequence of increased OC numbers, we analyzed the resorptive capacity of individual OCs by
plating committed OCs (differentiated on plastic with M-CSF and RANKL for 3 days) on bone
slices for 48 hours. Results show equivalent bone resorption by Tmem178-/- and WT OCs
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(Figure 3.2 J-K). Altogether these finding demonstrate that Tmem178 is a negative regulator of
OC differentiation, but does not exert a direct effect on the cell’s resorptive capacity.
Tmem178 negatively regulates OC formation by suppressing NFATc1 activation
To understand how Tmem178 modulates OC differentiation, we assessed activation of
RANKL signaling cascades including NF-B and MAPKs, JNK, ERK and p38. We find no
perceptible differences in NF-B and MAPK activation between WT and Tmem178-/- BMMs
(top) or preOCs (bottom) stimulated with RANKL (Figure 3.3 A). Similarly, M-CSF induction
of p-AKT and p-ERK is equivalent in both genotypes (Figure 3.3 B).
NFATc1 is another important pathway activated during osteoclastogenesis in response to
RANKL. Despite similar changes in NF-kB or MAPK activation, Tmem178-/- cells show
heightened NFATc1 total protein and transcript levels throughout osteoclastogenesis (Figure 3.3
C-D). Immunofluorescence staining of NFATc1 in BMMs shows only 1% of cells positive for
nuclear NFATc1 in both genotypes (Figure 3.3 E). However, after 24 and 48 hours of RANKL
stimulation, we observed a higher percentage of Tmem178-/- cells with NFATc1 nuclear
staining compared to WT (Figure 3.3 E). Consistent with this finding, we also found a striking
increase in NFATc1 nuclear translocation in Tmem178-/- preOCs compared to WT cells in
response to a RANKL time course (Figure 3.3 F). Notably, no differences in NFATc1 protein or
transcript levels are observed prior to RANKL exposure, indicating that Tmem178 acts
downstream of RANKL to regulate NFATc1 induction.
To confirm the proposed mechanism that Tmem178 suppresses osteoclastogenesis by
limiting NFATc1 levels, we ectopically expressed Tmem178 in WT BMMs and analyzed their
ability to induce NFATc1 and undergo OC differentiation. Tmem178-expressing cells show
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attenuated NFATc1 levels compared to empty vector controls (Figure 3.3 G), with a resulting
reduction in osteoclastogenesis (Figure 3.3 H, I). Altogether, these data indicate that Tmem178
modulates osteoclast differentiation by suppressing RANKL-induced NFATc1 activation.
Tmem178 modulates RANKL-induced Ca2+ fluxes
High NFATc1 levels in Tmem178-/- cells could result from increased transcriptional
activity of known NFATc1 regulators. IRF8 and Bcl6 are transcriptional repressors constitutively
bound to the NFATc1 promoter and down-regulated within 24 hours of RANKL-RANK
engagement [37]. qRT-PCR analysis revealed that mRNA levels of Bcl6 and IRF8 are reduced to
a similar extent and with equivalent kinetics in WT and Tmem178-/- cells during
osteoclastogenesis (Figure 3.4 A, B). Thus, Tmem178 does not seem to modify NFATc1 levels
by targeting its transcriptional regulators.
Alternatively, cytosolic Ca2+ fluxes stimulate the calmodulin/calcineurin pathway
activating NFATc1 nuclear translocation. To test whether Tmem178 may restrain NFATc1 by
affecting Ca2+ mobilization, we utilized ratiometric confocal imaging to measure Ca2+ in preOCs.
Cells were loaded with Fura-2, a fluorescent Ca2+-binding dye; the ratio of Fura-2 fluorescence
intensity following excitation at 340 and 380nm reflects intracellular Ca2+ concentration
([Ca2+]i). The addition of exogenous RANKL induces the expected cytosolic Ca2+ oscillations in
WT cells (Figure 3.4 C, average of 40-50 fluxing cells per genotype) while an immediate spike
followed by sustained [Ca2+]i occurs in Tmem178-/- preOCs. Higher basal [Ca2+] i are already
noted in Tmem178-/- preOC prior to the acute addition of RANKL. Quantification of the
average Ca2+ measurements prior to any stimulation demonstrates that the majority of WT
preOCs have a 340/380 ratio less than 1.0, while more than 60% of Tmem178-/- cells show a
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340/380 ratio between 1.0-2.0 (Figure 3.4 D, more than 120 cells/genotype, data pooled from 3
independent experiments). These data suggest that Tmem178 is a novel negative regulator of
[Ca2+]i in the OC.
To understand whether Tmem178 regulates cytosolic Ca2+ levels by affecting the ER
pool or the extracellular exchange, we sought to first define Tmem178’s cellular localization. We
expressed HA-tagged Tmem178 fusion protein (Tmem178-HA) in a puromycin-resistant
retroviral vector in primary BMMs. Empty vector-expressing cells were used as a negative
control. Cells surviving antibiotic selection were differentiated into OCs. Using phalloidin to
stain polymerized actin at the cell membrane and calnexin as an ER marker, we found that
Tmem178-HA localizes to the ER in mature OCs (Figure 3.4 E-F).
We next wanted to examine how Tmem178 functions in the ER to modulate Ca2+
mobilization. WT and Tmem178-/- preOCs were treated with thapsigargin (Tg) in Ca2+-free
buffer to measure ER Ca2+ release. Tmem178-/- preOCs show a greater increase in cytoplasmic
[Ca2+] compared to WT cells (Figure 3.4 G). Importantly, this is not due to an increase in ER
Ca2+ content, as ionomycin-triggered ER Ca2+ depletion in the presence of the Ca2+ chelator
EGTA is equivalent in WT and Tmem178-/- preOCs (Figure 3.4 H, average of at least 70
cells/condition and representative of 3 independent experiments).
To confirm the role of Tmem178 as a negative regulator of ER Ca2+ mobilization, we
expressed ectopic Tmem178 or pMX empty vector control in HEK293T cells. Upregulation of
Tmem178 causes a slower and reduced increase in cytosolic [Ca2+] in response to Tg compared
to cells transfected with pMX alone (Figure 3.4 I). Again, this effect is not due to a change in
total ER Ca2+ concentration, as ionomycin-induced ER Ca2+ emptying is unchanged in
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Tmem178-expressing cells versus controls (Figure 3.4 J). Suppression of ER Ca2+ release is in
line with reduced NFATc1 expression and decreased osteoclastogenesis in primary OCs
expressing exogenous Tmem178 (Figure 3.3 G- I). Taken together, these data establish the
importance of Tmem178 as a negative regulator of ER Ca2+ mobilization.
Tmem178 associates with Stim1
Next, we wanted to know if Tmem178 interacts with known ER-resident proteins
involved in Ca2+ mobilization. Inositol triphosphate receptors (IP3Rs) are ER-resident Ca2+
channels, which facilitate ER Ca2+ release and consequent intracellular Ca2+ fluxes in response to
IP3 generated by PLC signaling. All IP3Rs have been shown to be expressed in the OC, and
IP3R2 and IP3R3 are compulsory for the generation of RANKL-stimulated Ca2+ fluxes [24].
Thus, we hypothesized that Tmem178 may be modulating ER Ca2+ mobilization by interacting
with IP3Rs. However, using co-immunoprecipitation and immunofluorescence approaches, we
were unable to detect the interaction between Tmem178 and any IP3Rs in primary OCs (data not
shown).
Stim1 is a transmembrane ER Ca2+ sensor which interacts with numerous Ca2+ channels
and adaptor proteins to regulate Ca2+ fluxes. Stim1 is expressed by the OC and regulates storeoperated Ca2+ entry (SOCE) through the association with Orai1. Targeting Stim1-mediated
calcium entry suppresses osteoclastogenesis [25-27]. While Stim1 deletion abolishes SOCE, a
modest defect in ER Ca2+ release was also previously noted in Stim1-deficient mast cells (Baba
et al, 2008). Interestingly, new evidence suggests that Stim1 can potentiate IP3R-mediated ER
Ca2+ release [38]. To determine if Tmem178 can bind Stim1, we expressed Tmem178-HA alone
and in combination with Stim1-Myc in HEK293T cells. By immunoprecipitation of Tmem178-
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HA followed by Western blot for Stim1-Myc, we detected the association between Tmem178
and Stim1 (Figure 3.5 A, first lane). No bands were observed in cell lysates that did not express
Stim1-Myc or in the IgG control (Figure 3.5 A second and third lane). Because Stim1 is best
described for its coupling with Orai1, we also expressed Orai1-FLAG (Figure 3.5 B, C). We
again found that Tmem178 and Stim1 interact, regardless of Orai1 expression (Figure 3.5 B,
middle lane and Figure 3.5 C, third lane). In reciprocal co-IPs, we did not detect any interaction
between Orai1 and Tmem178 (Figure 3.5 B, lane 1, Figure 3.5 C, bottom panel, lane 3),
indicating that Tmem178 specifically interacts with Stim1. Additionally, the Stim1-Orai1
interaction is intact in the presence of Tmem178 (Figure 3.5 C, first and second lanes). These
data indicate that Tmem178 binds to Stim1, but not Orai1.
To determine whether Tmem178 and Stim1 interact in primary cells, we transduced WT
BMMs with Tmem178-HA and Stim1-Myc retroviral vectors and cultured the expressing cells
with RANKL for 24 hours. By confocal microscopy, we found that Tmem178 and Stim1 colocalize in areas adjacent to the nuclei, presumably the ER (Figure 3.5 D, 4 representative fields).
Stim1 is most well-described in its role to activate store-operated Ca2+ entry (SOCE). To
assess whether Tmem178 alters SOCE, we incubated Tmem178-/- preOCs and their WT
counterpart with Tg in Ca2+-free buffer to deplete ER Ca2+ stores, followed by addition of 1.8
mM Ca2+ to the medium. As shown in Figure 3.5 E, both genotypes achieve similar cytoplasmic
Ca2+ concentrations in response to exogenous Ca2+ stimulation. A similar result was obtained in
HEK293T cells expressing ectopic Tmem178 versus pMX vector control (Figure 3.5 F).
Altogether, these findings indicate that Tmem178 is an ER protein that associates with Stim1.
Tmem178 does not appear to participate directly in SOCE, however, but rather regulates Ca2+
mobilization out of the ER.
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Tmem178-/- mice suffer profound inflammatory osteolysis
Having shown that Tmem178 restrains ER Ca2+ mobilization to affect NFATc1
upregulation and RANKL-induced OC differentiation, we wondered if Tmem178 similarly
regulates OC formation driven by inflammatory cytokines. First, we observed that Tmem178
mRNA expression is significantly increased in BMMs following exposure to inflammatory
stimuli, including LPS (not shown). Second, we observed that the addition of TNF- or LPS,
potent activators of pathological osteolysis, further exacerbates Tmem178-/- OC differentiation
in vitro (Figure 3.6 A). Moreover, Tmem178-/- mice injected with LPS over the calvaria develop
twice the eroded area compared to WT controls (Figure 3.6 B-C). This striking increase in
resorption corresponds to a significant increase in OC surface in Tmem178-/- mice as shown in
TRAP-stained histological sections (Figure 3.6 D-E).
Next, we wanted to determine whether Tmem178 could modulate focal osteolysis in a
model of inflammatory arthritis. Animals were injected with arthritogenic serum from K/BxN
mice on days 0, 2, and 6 and sacrificed on day 14. Despite developing an equivalent
inflammatory response to WT, measured by paw thickness and local production of inflammatory
cytokines (data not shown), Tmem178-/- mice suffer significantly more bone loss, measured by
remaining bone volume at the knee by CT (Figure 3.6 F-G), Analysis of the TRAP-stained
histological sections of arthritic bones revealed that the excessive erosion in Tmem178-/- mice is
driven by a significant increase in OC differentiation (Figure 3.6 H). All together these data
indicate that loss of Tmem178 drives robust OC formation and excessive bone loss in
inflammatory conditions.
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Based on the above observations, we wondered whether changes in Tmem178 levels
would be detected in patients affected by inflammatory conditions accompanied by bone erosion
and increased osteoclastogenesis. Systemic juvenile idiopathic arthritis (sJIA) is a chronic
disease characterized by systemic inflammation and arthritis [39]. Importantly, sJIA patients
present with joint inflammation and erosive disease despite blockade of inflammatory cytokines
[40, 41]. Low bone mass and increased risk of fragility fractures often persist in adulthood [5].
Thus, we hypothesized that sJIA pathogenesis may be related to Tmem178 dysregulation. Due to
the difficulty of obtaining sufficient cellular samples from pediatric patients, we utilized the
plasma of sJIA patients, which contains circulating factors capable of activating healthy human
CD14+ PBMCs [42, 43]. We cultured CD14+ PBMCs from healthy donors with M-CSF and
RANKL for 2 days to generate preOCs, and then added the plasma collected from healthy
controls (n = 10) or sJIA patients (n = 20). Interestingly, we observed a significant reduction in
Tmem178 transcript in CD14+ PBMCs treated with sJIA plasma compared to healthy control
plasma (Figure 3.6 I). Confirming the Tmem178-/- OC phenotype, the addition of sJIA plasma
potently augments OC differentiation compared to healthy plasma (Figure 3.6 J-K). Tmem178
expression is further reduced, while OC numbers are significantly increased, following exposure
to plasma from 5 patients with erosive disease compared to controls (Figure 3.6 I-K). Taken
together, these data indicate that downregulation of Tmem178 levels may drive excessive
osteoclastogenesis and contributes to erosive disease in sJIA.
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3.6 Discussion
Basal and pathological OC differentiation is dependent on Ca2+ fluxes initiated by the
cytokine RANKL to activate the transcription factor NFATc1 [6, 8, 44]. Here we identify for the
first time a role for Tmem178 as a negative regulator of NFATc1 by specifically limiting Ca2+
release from the ER (Figure 3.7). Tmem178 is upregulated by RANKL to restrain excessive OC
differentiation in mice and humans. Tmem178 deficiency induces osteopenia, owing to a
significant increase in OC numbers, and this phenotype becomes even more pronounced during
inflammatory conditions in both mice and sJIA patients. This work provides new evidence for
the importance of stringent control of Ca2+ mobilization to maintain bone mass and protect from
pathological osteolysis.
Amplitude and duration of dynamic Ca2+ signals have been shown to differentially
modulate activation of various transcription factors. NFAT proteins have enhanced Ca2+
sensitivity compared to other transcription factors such as NF-kB or JNK, which enables NFAT
transcriptional activation by low Ca2+ levels [45]. In the OC, a low but prolonged Ca2+ signal
induces NFATc1 nuclear translocation and long-lasting nuclear localization throughout the
osteoclastogenic process. We find that Tmem178-/- OC have higher basal intracellular Ca2+
levels than WT. Furthermore, in the OC, not only the amplitude of Ca2+ signaling but also the
generation of continuous Ca2+ oscillations through the reduction and refilling of ER Ca2+ in
response to RANKL is required for efficient NFATc1 transcriptional activation. Following
RANKL exposure, Tmem178-/- cells reach higher intracellular Ca2+ levels compared to WT
which correlate with greater NFATc1 induction and increased NFATc1 nuclear translocation.
Consequently, Tmem178-/- cells undergo more rapid and robust osteoclastogenesis. We show
that Tmem178 selectively modulates ER Ca2+ release, while not interfering with total ER Ca2+
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content or Ca2+ entry from the extracellular milieu. This result would suggest that Tmem178
prevents Ca2+ leakage from the ER. In support of this assumption, ectopic expression of
Tmem178 reduces thapsigargin-induced ER Ca2+ release and consequently suppresses NFATc1
induction and osteoclastogenesis. It is important to note that ER Ca2+ leakage is only a fraction
of the intracellular Ca2+ that can enter from the extracellular milieu. However, consistent with the
differential functional consequences of Ca2+ signaling patterns, such as oscillations and spikes,
this small but incremental difference in intracellular Ca2+ concentrations in KO cells exposed to
RANKL can account for the heightened osteoclastogenic response that we observe in vitro and
that persists in vivo.
Due to the importance of Ca2+ amplitude and duration in discriminating between different
response pathways, Ca2+ levels in the cells are tightly regulated. Regulators of Ca2+ channel
activity in the OC have only recently come under investigation. Ong et al described the
importance of transient receptor potential cation channel 1 to enhance store-operated calcium
entry (SOCE) from the extracellular milieu during OC formation [46]. Similarly, Tmem64
promotes RANKL-induced Ca2+ oscillations by bolstering the activity of Sarco-Endoplasmic
Reticulum ATPase isoform 2, which actively re-fills ER Ca2+ stores, and is required for
NFATC1 induction and osteoclastogenesis [28, 29, 47]. While these studies demonstrate that the
loss of positive regulators of Ca2+ fluxes perturbs osteoclastogenesis and leads to increased bone
mass, our work on Tmem178 is the first to identify a negative regulator of Ca2+ mobilization,
whose ablation leads to an osteopenic phenotype. The relevance of our findings is bolstered by
the significant reduction of Tmem178 expression levels in monocytes treated with plasma from
sJIA patients with erosive disease.
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In pursuing the mechanism by which Tmem178 modulates Ca2+ oscillations, we found
that Tmem178 and Stim1 co-immunoprecipitate. Stim1 is an ER Ca2+ sensor expressed in
numerous cell types, including OCs, lymphocytes, mast cells, B cells, and T cells.
Pharmacological inhibition of Stim1 impairs SOCE, thereby blocking osteoclastogenesis [27]. In
addition to associating with Orai1 to control SOCE, Stim1 also couples to numerous other Ca2+
channels, Ca2+ pumps, ER chaperone proteins, and regulatory adaptor proteins, thereby
influencing multiple pathways of Ca2+ transport [48]. In kidney epithelial cells, Stim1 interacts
with polycystin-1, diminishing IP3R-mediated ER Ca2+ release [49]. Most recently, Stim1 has
been shown to potentiate IP3R-mediated ER Ca2+ release in aortic endothelial cells [38]. In
muscle cells Stim1 inhibits Ca2+ discharge from the sarcoplasmic reticulum [50]. Differences in
ER Ca2+ release were also noted in Stim1-/- mast cells in response to antigen or thapsigargin
[51]. Thus, Stim1 has a critical role not only in sensing ER Ca2+ levels and activating SOCE, but
also appears to regulate, at least in part, ER Ca2+ release in multiple cell types. In the OC, we
find that Tmem178 localizes to the ER where it associates with Stim1. Interestingly, Tmem178
does not bind to Orai1 or inhibit Orai1-Stim1 coupling, and Orai1/Stim1-mediated Ca2+ entry is
similar in both genotypes. Tmem178 also does not appear to associate with IP3Rs. While further
studies are necessary to wholly understand the mechanism of Tmem178-mediated ER Ca2+
regulation and the significance of the Tmem178-Stim1 complex, we believe the Tmem178-Stim1
interaction is an important observation which expands the understanding of Ca2+ regulation in
the OC.
Tmem178 interaction with Stim1 is particularly interesting in the context of arthritis.
Stim1 single nucleotide polymorphisms (SNPs) were recently identified in patients with
ankylosing spondylitis (AS), a chronic inflammatory disease of the spine and joints [52]. These
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SNPs correlated with significantly higher inflammatory markers including C-reactive protein and
in some cases higher circulating levels of TNF- and IL-6. In unpublished data, we found that
Tmem178 negatively regulates TNF-, IL-1, and IL-6 production by macrophages. Although we
did not have access to patient samples to measure Tmem178 levels or Tmem178/Stim1 binding
in AS, we found that reduced Tmem178 expression is associated with augmented
osteoclastogenesis in the context of sJIA. Further supporting a role for Tmem178 in
inflammatory arthritis, Tmem178-/- mice suffer profound osteolysis following LPS and in
K/BxN arthritis and in vitro studies show increased responsiveness to TNF-induced
osteoclastogenesis.
sJIA is characterized by arthritis and systemic inflammation. Bone erosion and systemic
bone loss were observed in up to 50% of children with sJIA in the pre-biologic era. Even more
recently, CARRAnet registry data (collected since 2010) on 435 children with sJIA show that
joint damage remains a significant problem for at least 20% of these patients despite remission of
the systemic inflammation (Janow et al., manuscript submitted). Low bone mass and high risks
of fragility fractures are also seen in adult patients who suffered from sJIA during childhood and
adolescence [5]. Unfortunately, there are no markers that identify the subset of sJIA patients who
will develop erosive disease. Further, the diagnosis of sJIA is a clinical diagnosis of exclusion,
and unfortunately a delayed diagnosis contributes to the development of erosive changes. We
now show that Tmem178 expression is significantly reduced in human CD14+ PBMCs exposed
to sJIA plasma, while OC differentiation is increased. We also observe a significant reduction in
Tmem178 levels in samples treated with plasma from sJIA patients with erosive disease,
positioning Tmem178 as a potential biomarker for the subset of sJIA patients who will develop
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erosive disease. These initial findings with a limited number of patient samples necessitate future
investigations with larger cohorts of sJIA patients.
Mechanistically, we do not yet understand the complex upstream mechanism which
regulates Tmem178 expression in response to sJIA plasma. Moreover, in unpublished studies we
find that Tmem178 also participates in inflammatory cytokine production, raising the possibility
that Tmem178 may be important not only to the erosive aspect of sJIA but could contribute to
the autoinflammatory symptoms of disease. Further investigation into the role of Tmem178 in
the pathogenesis of sJIA is warranted.
In conclusion, we have identified Tmem178 as a new PLC2-dependent gene. Despite its
dependence on the RANKL-PLC2 pathway, however, Tmem178 acts in a negative feed back
loop to restrain osteoclast responses in basal and pathological conditions. Moreover, we
characterized the mechanism of Tmem178 to specifically modulate ER Ca2+ mobilization to
repress NFATc1 induction.
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3.9 Figure Legends
Figure 3.1. Deletion of Tmem178 decreases bone mass in basal conditions
A. Quantitative real-time PCR analysis of Tmem178 mRNA in whole tissues harvested from
WT or PLC2-/- mice. Expression levels of Tmem178 were normalized to cyclophilin
B. Representative images of microcomputed tomography (CT) of the proximal femurs of
16 week-old female WT and Tmem178-/- mice. WT n = 10, Tmem178-/- n = 11
C. Trabecular bone volume per tissue volume (BV/TV) quantified from CT shown in (B).
Data represent mean ± SD. Two-tailed student’s T-test was used to assess statistical
significance, * p < 0.05
D. Trabecular thickness (Tb.Th.) quantified from CT shown in (B). Data represent mean ±
SD. Two-tailed student’s T-test was used to assess statistical significance, * p < 0.05
E. Histological analysis of femurs analyzed in (B). Femurs were stained with TRAP to
detect OCs and counterstained with hematoxylin. Arrows indicate OCs.
F. Quantification of OC surface per bone surface (Oc.S/B.S.) in (E). n = 5/genotype. Data
represent mean ± SD. Two-tailed student’s T-test was used to assess statistical
significance, * p < 0.05
G. Dynamic histomorphometry of calvaria from 4 week-old WT and Tmem178-/- mice
labeled with calcein and alizarin red.
H. Quantification of bone formation rate (BFR) of (G). n = 5/genotype. Data represent mean
± SD. Two-tailed student’s T-test was used to assess statistical significance, * p < 0.05
I. Quantification of mineral apposition rate (MAR) of (G). n = 5/genotype. Data represent
mean ± SD. Two-tailed student’s T-test was used to assess statistical significance, * p <
0.05
Figure 3.2. Tmem178 deficiency enhances osteoclastogenesis
A. Quantitative real-time PCR analysis of Tmem178 mRNA in WT BMMs, mature OCs,
and mature OBs cultured in vitro. Expression levels of Tmem178 were normalized to
cyclophilin levels.
B. Quantitative real-time PCR analyses of Tmem178 mRNA during RANKL-induced
osteoclastogenesis in vitro in WT and PLC2-/- cells. WT and PLC2-/- BMM were
cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for the indicated days. Expression
levels of Tmem178 were normalized to cyclophilin levels. Representative of 3
experiments.
C. Quantitative real-time PCR analysis of Tmem178 mRNA in human CD14+ PBMCs
cultured in vitro with 50 ng/ml RANKL for indicated time points. Expression levels of
Tmem178 were normalized to cyclophilin levels. Data represent mean ± SD. Two-tailed
student’s T-tests was used to assess statistical significance, * p < 0.05
D. Expression of Tmem178 mRNA during RANKL-induced osteoclastogenesis in vitro in
control (NFATc1fl/fl) and NFATc1-deficient cells (NFATc1Δ/Δ). Controls and NFATc1Δ/Δ
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E.

F.

G.

H.

I.
J.

K.

BMMs were cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for the indicated
days. Tmem178 expression levels were normalized to cyclophilin. Data represent mean ±
SD. Two-tailed student’s T-test was used to assess statistical significance, * p < 0.05.
TRAP staining of WT and Tmem178-/- OCs in vitro after 4 days of culture with 10 ng/ml
M-CSF and 50 ng/ml RANKL. Images are representative of more than 5 experiments,
each performed in triplicate.
Quantification of TRAP+ OCs in WT and Tmem178-/- cultures after 3 and 4 days of
culture with 10 ng/ml M-CSF and 50 ng/ml RANKL. Triplicate wells were counted for
each condition, and data are representative of more than 5 experiments. Data represent
mean ± SD, * p < 0.05, *** p < 0.001
Quantitative real-time PCR analysis of osteoclastogenic markers in WT and Tmem178-/cells collected at the indicated days of culture with 10 ng/ml M-CSF and 50 ng/ml
RANKL. Acp5, TRAP; Ctsk K, Cathepsin K. CalcR, calcitonin receptor. Expression
levels of each marker were normalized to cyclophilin. Data represent the mean ± SD, **
p < 0.01, *** p < 0.0001, n = 3 independent experiments
Representative bright field images of resorptive pits in WT and Tmem178-/- cultures.
WT and Tmem178-/- BMMs were cultured on bovine bone slices in the presence of 10
ng/ml M-CSF and 50 ng/ml RANKL for 10 days. Resorption pits were visualized by
staining with peroxidase-conjugated wheat-germ agglutinin. Black lines delineate the
resorbed areas.
Quantification of resorbed area in images from (H). n = 8-9/ genotype. Data represent
mean ± SD, * p < 0.05.
Representative bright field images of resorptive pits in WT and Tmem178-/- cultures.
WT and Tmem178 BMM were cultured on plastic dishes with 10 ng/ml M-CSF and 50
ng/ml RANKL for 3 days. Cells were then lifted and re-plated on bovine bone slices in
the presence of 10 ng/ml M-CSF and 50 ng/ml RANKL for 48 hours. Resorption pits
visualized by staining with peroxidase-conjugated wheat-germ agglutinin. Black lines
delineate the resorbed areas.
Quantification of resorbed area in images from (J). n = 8-9/ genotype. Data represent
mean ± SD, ns

Figure 3.3. Tmem178 negatively regulates the Ca2+-NFATc1 signaling pathway
A. Western blot analysis of RANKL-induced MAPK and NFWT and Tmem178-/- BMMs were serum- and cytokine- starved overnight, and
stimulated with 50 ng/ml RANKL for the indicated time points. Total Pyk2 is shown as
loading control. Bottom panels- WT and Tmem178-/- preOCs were cultured with 10
ng/ml M-CSF and 50 ng/ml RANKL for 2 days, serum- and cytokine-starved for 6 hours,
and stimulated with 50 ng/ml RANKL for the indicated time points. Actin is shown as
loading control. Representative of 3 experiments.
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B. Western blot analysis of M-CSF-induced AKT and ERK phosphorylation. Top panelsWT and Tmem178-/- BMMs were serum- and cytokine- starved overnight, and
stimulated with 100 ng/ml recombinant M-CSF for the indicated time points. Total Pyk2
is shown as loading control. Bottom panels- WT and Tmem178-/- preOCs were cultured
with 10 ng/ml M-CSF and 50 ng/ml RANKL for 2 days, serum- and cytokine-starved for
6 hours, and stimulated with 100 ng/ml M-CSF for the indicated time points. Actin is
shown as loading control. Representative of 3 experiments.
C. Western blot analysis of NFATc1 total protein levels at the indicated time points of
osteoclastogenesis. WT and Tmem178-/- BMMs were cultured with 10 ng/ml M-CSF
and 50 ng/ml RANKL for the indicated number of days. Total ERK levels are shown as
loading control. Representative of 3 experiments.
D. Quantitative real-time PCR analysis of NFATc1 mRNA at the indicated days of
osteoclastogenesis. WT and Tmem178-/- BMM were cultured with 10 ng/ml M-CSF and
50 ng/ml RANKL for the indicated number of days. NFATc1 expression levels were
normalized to cyclophilin. Data represent the mean ± SD, ** p < 0.01, n = 3 independent
experiments
E. Quantification of NFATc1 nuclear localization by immunofluorescence. WT and
Tmem178-/- BMMs were plated on glass coverslips and cultured with 10 ng/ml M-CSF
and 50 ng/ml RANKL for the indicated number of days. Data are pooled from 2
independent experiments, 3-9 coverslips/condition/experiment. Cells were stained for
NFATc1 and DAPI to detect nuclei. Data represent the mean ± SD, * p < 0.05
F. Western blot analysis of NFATc1 nuclear translocation in response to RANKL. WT and
Tmem178-/- BMMs were cultured with 10 ng/ml M-CSF and 50 ng/ml RANK for 2
days, serum- and cytokine- starved for 6 hours, and stimulated with 50 ng/ml RANKL for
the indicated time points. Lamin B is shown as loading control. Representative of 3
experiments.
G. Quantitative real-time PCR analysis of NFATc1 transcript levels during
osteoclastogenesis in WT cells expressing empty vector pMX or Tmem178-HA. BMMs
expressing pMX or Tmem178-HA were cultured with 10 ng/ml M-CSF and 50 ng/ml
RANKL for the indicated number of days. NFATc1 expression levels were normalized to
cyclophilin. Data represent the mean ± SD, ** p < 0.01, *** p < 0.0001, n = 3
independent experiments
H. Representative images of TRAP staining of OCs expressing pMX empty vector or
Tmem178-HA in vitro after 4 days of culture with 10ng/ml M-CSF and 50ng/ml
RANKL.
I. Quantification of OC area in (h). Data represent the mean ± SD, ** p < 0.01, n =
3/condition, representative of more than 3 experiments.
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Figure 3.4. Tmem178 modulates ER Ca2+ mobilization
A. Quantitative real-time PCR analysis of Bcl6 transcript levels during osteoclastogenesis in
WT and Tmem178-/- cells cultured with 10ng/ml M-CSF and 50ng/ml RANKL for the
indicated days. Bcl6 expression levels were normalized to cyclophilin. Data represent the
mean ± SD. n = 3 independent experiments.
B. Quantitative real-time PCR analysis of IRF8 transcript levels during osteoclastogenesis in
WT and Tmem178-/- cells cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for the
indicated days. IRF8 expression levels were normalized to cyclophilin. Data represent
then mean ± SD. n = 3 independent experiments.
C. Cytosolic Ca2+ measurements in primary preOC by ratiometric confocal imaging. WT
and Tmem178-/- BMMs were cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for
1-2 days to generate preOCs. Cells were loaded with 3M Fura-2 in phenol red-free
DMEM and stimulated with 100ng/ml RANKL in the presence of extracellular Ca2+. 5
representative tracings of single cells are shown for WT and Tmem178-/- preOC.
D. Percent of WT and Tmem178-/- preOCs with low Ca2+ (Fura-2 ratio < 1) or high Ca2+
(Fura-2 ratio >1). The Fura-2 ratio of each cell was averaged over the first 60 seconds of
imaging. Data was pooled from 3 experiments, combining more than 120 cells/genotype.
E-F. Localization of Tmem178 in mature OCs by immunofluorescence. BMMs expressing
pMX or Tmem178-HA were cultured on coverslips with 10ng/ml M-CSF and
100ng/ml RANKL for 5 days. Phalloidin was used as a plasma membrane marker,
calnexin was used as an ER marker and DAPI was used as a nuclear stain. Scale bar
indicates 100 m. Manually contoured white line denotes cell edge.
G. ER Ca2+ release measured by ratiometric confocal imaging of primary WT and
Tmem178-/- preOCs, imaged in the presence of Ca2+-free HBSS and treated with 1 M
Tg to measure ER Ca2+ release. Fura-2 340/380 ratios are the mean of at least 70
cells/condition, representative of 3 independent experiments.
H. Total ER Ca2+ content measured by ratiometric confocal imaging of primary WT and
Tmem178-/- preOCs, imaged in the presence of Ca2+-free HBSS containing 2mM EGTA.
Cells were stimulated with 10M ionomycin to trigger ER Ca2+ depletion. Fura-2
340/380 ratios are the mean of at least 70 cells/condition, representative of 3 independent
experiments.
I. ER Ca2+ release detected by ratiometric imaging of cytosolic Ca2+ of HEK293T cells
2+
expressing empty vector or Tmem178-HA. C
-free
2+
HBSS to measure ER Ca release. Fura-2 340/380 ratios represent the mean of at least
100 cells/condition, representative of 2 independent experiments.
J. Total ER Ca2+ content detected by ratiometric confocal imaging of HEK293T cells
2+
expressing empty vector or Tmem178-
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free HBSS containing 2mM EGTA. Fura-2 340/380 ratios represent the mean of at least
100 cells/condition. representative of 2 independent experiments.
Figure 3.5. Tmem178 associates with Stim1 in the ER
A. Co-immunoprecipitation of Tmem178 and Stim1. Top panel- HEK293T cells expressing
Tmem178-HA alone or with Stim1-Myc were lysed, and subjected to
immunoprecipitation with anti-HA antibody or control IgG. IP WB was probed with Myc
tag antibody. Total cell lysates were blotted for Myc and HA.
B. Co-immunoprecipitation of Tmem178 and Stim1 in HEK293T cells expressing
Tmem178-HA, Stim1-Myc, and Orai1-FLAG. Top panel-lysates were subjected to
immunoprecipitation with anti-FLAG, anti-Myc, or IgG control antibodies, and Western
blotted for HA to detect an association with Tmem178. Total cell lysates (bottom panel)
were probed for FLAG, Myc, and HA to show co-expression of all proteins.
C. Co-immunoprecipitation of Stim1 with Tmem178 and Orai1. HEK293T cells expressing
Tmem178-HA, Stim1-Myc, and Orai1-FLAG were immunoprecipitated with the
indicated antibodies and Western blotted for Myc and FLAG (Top panel). Total cell
lysates (bottom panel) were probed for FLAG, Myc, and HA to show co-expression of all
proteins.
D. Representative confocal images of Tmem178 and Stim1 co-localization in primary cells.
BMMs co-expressing Tmem178-HA and Stim1-Myc were plated on glass coverslips in
the presence of 10 ng/ml M-CSF and 50 ng/ml RANKL for 24 hours. Cells were stained
with a FITC-conjugated anti-HA antibody and anti-Myc tag antibody. Myc was detected
using an Alexa Fluor 543 secondary antibody. Dapi was used for nuclear staining.
E.-F. SOCE was measured in WT and Tmem178-/- cells cultured with 10 ng/ml M-CSF and 50
ng/ml RANKL for 24 hours (E) and HEK293T cells expressing empty vector or ectopic
Tmem178 (F). Cells were loaded with 3 M Fura-2 in Ca2+-free HBSS then treated
with Thapsigargin (Tg) to release ER Ca2+. 1.8 mM Ca2+ was then added back to the
buffer to measure SOCE.
Figure 3.6. Tmem178 deletion worsens inflammatory bone loss
A. Quantification of TRAP+ OCs in WT and Tmem178-/- cells cultured with 10 ng/ml MCSF and 100 ng/ml RANKL alone, or with the addition of 100 ng/ml LPS or 10 ng/ml
TNF- on day 2 of OC culture. Data represent the mean ± SD, *** p < 0.0001 ** p <
0.01, n = 3
B. Representative CT 3D reconstructions of calvaria from WT and Tmem178-/- mice
receiving 100 µg supracalvarial LPS on day 0. Calvaria were harvested on day 5 after
LPS.
C. Quantification of the percent area resorbed on the calvaria from images shown in (B).
Data represent the mean ± SD, ** p < 0.01, n = 10/genotype
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D. Representative images of histological sections from calvaria shown in (B) stained with
TRAP to detect OCs and counterstained with hematoxylin. Arrows indicate OCs.
E. Quantification of TRAP+ OC in (D). Data are expressed as OC surface per bone surface
(Oc.S./B.S.). Data represent the mean ± SD, ** p < 0.01, n = 10/genotype
F.
-/- mice
harvested on day 14 after 3 injections of K/BxN serum on days 0, 2 and 6 to induce
inflammatory arthritis. n = 9/genotype.
G. Quantification of bone volume remaining at the knee in mice in (F). Data represent the
mean ± SD, ** p < 0.01, n = 10/genotype
H. Quantification of TRAP+ OCs on TRAP-stained histological sections from knees of WT
and Tmem178-/- mice in (F) . Data are expressed as OC surface per bone surface
(Oc.S/B.S.) Data represent the mean ± SD, ** p < 0.01, n = 10/genotype
I. Quantitative real-time PCR analysis of Tmem178 mRNA expression in human CD14+
PBMCs from healthy donor were cultured with 30 ng/ml hM-CSF and 100 ng/ml
RANKL for 2 days. Plasma from healthy controls or sJIA patients was added to the
cultures for 8 hours. Tmem178 expression is normalized to cyclophilin expression. Data
represent the mean ± SD, ** p < 0.01, * p < 0.05.
J. Quantification of area covered by TRAP+ OCs cultured with healthy control plasma or
sJIA patient plasma. Human CD14+ PBMCs from healthy donor were cultured with 30
ng/ml hM-CSF and 100 ng/ml RANKL for 5 days. Plasma from healthy controls or sJIA
patients was added on day 2 of osteoclastogenesis and replenished at media change every
other day. Data represent the mean ± SD, * p < 0.05. Triplicate wells were counted for
each plasma sample, and data are representative of 3 independent experiments.
K. Representative images of TRAP staining of OCs treated with healthy control plasma or
sJIA patient plasma quantified in (j)
Figure 3.7. Model of Tmem178 function.
In the WT OC, Tmem178 represses ER Ca2+ release, thereby limiting cytosolic Ca2+,
NFATc1 activation, and osteoclastogenesis. In Tmem178-/- OCs, augmented ER Ca2+
release increases cytosolic Ca2+ levels, thereby amplifying NFATc1 activation leading to
excessive osteoclastogenesis.
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Chapter 4. The Role of Tmem178 in the Regulation of the Macrophage Inflammatory
Response
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4.1 Up-regulation of Tmem178 in inflammatory macrophages is essential to the control of
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4.2 Abstract
Pathological bone loss in human disease such as rheumatoid arthritis is largely due to
excessive osteoclast recruitment and activation as a consequence of localized inflammation.
PLC2-deficient mice are protected from inflammatory arthritis due to impaired neutrophil
inflammatory responses. We now report that PLCγ2-/- bone marrow macrophages (BMM)
display impaired NF-kB activation leading to reduced IL-1, IL-6 and TNFα mRNA levels
following adhesion, suggesting that PLCγ2 controls the development of inflammation in innate
immune cells. By a gene array approach, we identified Tmem178 as a novel PLC2 effector
whose expression is highly induced by integrin-mediated adhesion and TLR activation in WT
but not PLC2-/-macrophages. In contrast to PLC2-/- macrophages, we find that Tmem178-/BMMs have a striking increase in inflammatory cytokine expression in response to adhesion and
TLR stimulation. Mechanistically, Tmem178 targets Ca2+ fluxes downstream of TLR and
integrin signaling to affect NFAT activation, thus dampening inflammatory cytokine
transcription. Most importantly, Tmem178-null mice succumb faster to endotoxin-induced
sepsis, indicating that Tmem178 functions in a novel negative feedback loop downstream of
PLCγ2 to repress inflammation. These results are consistent with our previous observation
reporting a reduction Tmem178 levels in the context of sJIA. Our data demonstrate a role for
Tmem178 in controlling inflammation as well, positioning Tmem178 as an essential regulatory
component in both the inflammatory and erosive arms of inflammatory arthritis.
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4.3 Introduction
In arthritic conditions, chronic inflammation drives activation of the bone-resorbing
osteoclast leading to bone resorption and progressive joint disease. An influx of leukocytes cells
into the joint is a hallmark of inflammatory arthritis. Innate immune cells, namely neutrophils
and macrophages, infiltrate the joint space and release pro-inflammatory cytokines including
TNF-a, IL-1, and IL-6 as well as proteases to drive local tissue damage and inflammation.
Importantly, IL-1 and TNF- in particular potently augment osteoclast differentiation and thus
bone resorption (1-7). Thus, suppressing the inflammatory response is fundamental to the
efficacy of arthritis treatments. Current therapeutics such as disease-modifying anti-rheumatic
drugs (DMARDs) and cytokine inhibitors, however, are not successful at controlling
inflammation in all patients (8).
Patients suffering from systemic juvenile idiopathic arthritis (sJIA) exhibit dramatically
elevated levels of inflammatory cytokines, specifically IL-1 and TNF-, within the synovial
fluid and in circulation (9, 10). sJIA is an episodic auto-inflammatory disease that, unlike other
arthritic subtypes, is primarily driven by innate immune cells. Expanded monocyte numbers,
particularly during episodes of disease flare, are observed in sJIA patients (9). Approximately
10% of sJIA patients develop MAS, which is responsible for the majority of the morbidities
associated with sJIA. The onset of MAS is sudden, and patients present with high fever,
hepatosplenomegaly, lymphadenopathy, cutaneous and mucosal bleeding, pancytopenia, as well
as central nervous system, cardiac, and renal involvement. Importantly, MAS is so-named due to
a massive influx of activated macrophages in the bone marrow, liver and spleen. (10, 11). It is
actually unknown if this increase in macrophages is driving pathogenesis or is an attempt to
control a dysregulated adaptive immune response (12). The sJIA/MAS field is currently lacking
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a clear picture of how the activated monocyte/macrophage population functions at both a cellular
and molecular level during the onset and course of disease.
We have previously reported that PLC2-deficient mice are osteopetrotic due to defective
OC formation and are protected from joint inflammation and destruction during serum-transfer
arthritis, a model strictly dependent on neutrophil and macrophage activation (13, 14). The
aberrant inflammatory response observed in PLCγ2-/- mice was dependent on reduced
production of inflammatory cytokines IL-1, IL-6 and TNF-α by local innate immune cells. We
also have previously shown that specifically targeting PLC2 scaffolding domains in vivo can
block the osteoclast and ameliorate the erosive pathology of inflammatory osteolysis, but this
approach is not sufficient to dampen inflammation (15). Thus, to better understand PLCg2dependent genes which could modulate a pro-inflammatory immune response we performed a
gene array comparing WT and PLC2-/- BMMs plated on integrin substrate. Herein we identify
Tmem178 as a novel molecule that represses the pro-inflammatory response of macrophages, in
vitro and in vivo. This observation in concert with our previous finding that Tmem178 levels are
reduced in CD14 monocytes exposed to plasma from sJIA patients, raise the possibility that
Tmem178 is a new gene of interest in the pathogenesis of sJIA and the associated disorder MAS.
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4.4 Materials and Methods
Mice
PLC2-/- mice were kindly provided by Dr. JN Ihle (St. Jude Children’s Research Hospital,
Memphis, Tennessee, USA). Tmem178-/- mice (Strain B6;129S5-Tmem178tm1Lex/Mmucd)
were generated by the trans-NIH Knock-Out Mouse Project (KOMP) and purchased from the
KOMP Repository at UC Davis (www.komp.org) (stock number 032664-UCD). Tmem178-/C57Bl/6-SvEv129 mice were transferred to the pure C57Bl/6 background by speed congenics,
and maintained on the C57Bl/6 background by homozygous breeding. Perforin-/- (prf-/-)
breeding pairs were purchased from Jackson Labs (Strain Name:C57BL/6-Prf1tm1Sdz/J Stock
Number: 002407) and maintained by homozygous breeding. C57Bl/6 Tmem178-perforin double
knock out mice were generated in-house. All experiments were approved by the Washington
University School of Medicine animal care and use committee.
Primary cell culture
Bone marrow was isolated from long bones of 6- to 8-week-old C57BL/6 mice and cultured in
alpha-MEM containing 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin, and 100
μg/ml streptomycin, and glutamine (α-10 medium), with 1/10 vol CMG14-12 cell-conditioned
medium as a source of macrophage colony-stimulating factor (M-CSF) (16) to obtain bone
marrow-derived macrophages (BMMs). Resident peritoneal macrophages were harvested from
6- to 8-week-old C56Bl/6 mice by lavage. Briefly, the peritoneum was washed with 4 ml of
sterile PBS, exudate was collected, and recovered cells were washed in sterile PBS. Cells were
cultured in vitro with DMEM containing 10% heat-inactivated fetal bovine serum, 100 IU/ml
penicillin, and 100 μg/ml streptomycin, and glutamine.
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Gene array
Petri dishes were coated with Arg-Gly-Asp (pRGD) in PBS overnight at 4°C. WT and PLCg2-/BMMs were serum- and cytokine- starved overnight, lifted with trypsin-EDTA, and 2 × 106 cells
were plated on pRGD-coated dishes for 4 hours. Non-adherent cells were in suspension for 4
hours. Cells were lysed in TRIzol and RNA was extracted by RNeasy Mini kit (Qiagen). mRNA
profiles were analyzed by Affymetrix Mouse Gene 430 2.0 array.
Western blot and antibodies
For signaling assays, BMMs were starved overnight in overnight in cytokine- and serum-free
alpha medium. For adhesion assays, petri dishes were coated with Arg-Gly-Asp (pRGD) in PBS
overnight at 4°C. Starved BMMs were lifted with trypsin-EDTA, and plated on pRGD-coated
dishes for the indicated time points. For LPS stimulation, starved BMMs were treated with 1
ug/ml LPS from Escherichia coli 0111:B4 (Sigma) in cytokine- and serum free alpha medium for
the indicated time points. For total cell lysates, BMMs or preOCs were lysed in RIPA buffer
supplemented with protease/phosphatase inhibitor cocktail (Pierce). Protein concentration was
determined by bicinchoninic acid protein assay (Biorad), resolved by SDS-page and subjected to
western blot analysis. For immunoblotting phospho-ERK (D13.14.4E), phospho-JNK (81E11),
phospho-p38 (3D7), phospho-IκBα (14D4), Pyk2 (3292), and ERK (9102) monoclonal
antibodies were obtained from Cell Signaling Technology. Actin was purchased from Sigma.
NFATc1 (7A6) was purchased from Santa Cruz, as well as secondary anti-mouse and anti-rabbit
HRP-conjugated antibodies.

123

Ratiometric Ca2+ imaging
For Ca2+ flux assays, 500 000 BMMs were seeded in 29mm glass bottom dishes (In Vitro
Scientific). Cells were cultured with 1 ug/ml LPS in alpha-mem media for 16 hours. Cells were
loaded with 3 M Fura-2-AM (Invitrogen) in phenol red-free DMEM (Invitrogen) .Cells were
washed twice with HBSS and imaged immediately in phenol red-free DMEM containing 1ug/ml
LPS. Fura-2 ratios were measured by alternate excitation at 340 nm and 380 nm. A Till
Photonics digital microscopes equipped with Polychrome V monochromators, Fura-2 (340/380)
filter set, a 20X 0.3NA objective lens, and high resolution (1344×1200) cooled CCD camera was
used to capture images at a frequency of 1 image pair every 2 seconds. Data were acquired and
analyzed using Live Acquisition software.
Real-time PCR
Adherent cells were lysed in Trizol. Total RNA was isolated using the RNeasy Mini Kit
(Qiagen) and reverse transcribed to cDNAs using EcoDry Premix (Oligo dT) (Clontech).1 μg of
total RNA was reverse transcribed to cDNA using SuperScript II according to the manufacturer’s
instructions (Invitrogen). For real-time PCR, SYBR Green PCR Master Mix (Applied
Biosystems) and primers specific for murine Tmem178, IL-1, IL-6, TNF-a, NFATc1, NFATc3,
and cyclophilin were used as follows for Tmem178, ATGACAGGGATATTTTGCACCAT
(forward) and CCGGTTCAAGTCATAGGAGACACT (reverse); IL-1,
GCTTCCTTGTGCAAGTGTCTGA (forward) and TCAAAAGGTGGCATTTCACAGT
(reverse); for IL-6, TTCTCTGGGAAATCGTGGAAA (forward) and
TGCAAGTGCATCATCGTTGTT (reverse); for TNFα, CTGTAGCCCACGTCGTAGC
(forward) and TTGAGATCCATGCCGTTG (reverse); for NFATc1,
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CCCGTCACATTCTGGTCCAT (forward) and CAAGTAACCGTGTAGCTGCACAA
(reverse); for NFATc3 GCTCGACTTCAAACTCGTCTT (forward) and
GATGTGGTAAGCCAAGGGATG (reverse) for cyclophilin AGCATACAGGTCCTGGCATC
(forward) and TTCACCTTCCCAAAGACCAC-3’ (reverse). SYBR green dye was used for
detection of the product using the SYBR Green PCR Master Mix assay (Applied Biosystems).
The standard curve used a series of duplicate dilutions of plasmid for each gene and cyclophilin
cDNA. The amplification reaction was performed for 40 cycles with denaturation at 95°C for 10
minutes, followed by annealing at 95°C for 15 seconds and extension and detection at 60°C for 1
minute. The relative abundance of each target was calculated as 1000×2−(Ct target gene−Ct
cyclophilin), where Ct represents the threshold cycle for each transcript, and cyclophilin is the
reference.
LPS-induced sepsis
WT and Tmem178-/- C57Bl/6 mice were injected with 25 mg/kg Lipopolysaccharides (LPS)
from Escherichia coli 0111:B4 (Sigma). Blood was collected by submandibular bleed 2 hours
after LPS administration, and serum was harvested by centrifugation at 8000g for 5 minutes at 4
degrees. Serum cytokines were measured using the mouse inflammatory cytometric bead array
(BD Biosciences).
LCMV-induced MAS
LCMV-WE viral stocks were kindly provided by Dr. Maria Salvato (University of Maryland).
For LCMV infections, mice were administered 104 PFU of LCMV-WE injected intravenously.
PBS- and clodronate-loaded liposomes were purchased from www.clodronateliposomes.org. For
macrophage depletion, mice were administered 200 ul of clodronate-loaded liposomes
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intravenously. Control mice received 200 ul of empty liposomes. Mice were monitored for
survival, or sacrificed on the indicated days for macrophage population analysis. To measure
serum cytokines, blood was collected via submandibular bleed and irradiated by exposure to UV
for 30 minutes. Serum was isolated via centrifugation at 8000 g for 5 minutes at 4 degrees.
Serum cytokines were measured using a mouse inflammatory Cytometric Bead Array (BD
Biosciences).
Flow cytometry
Immediately upon sacrifice, single-cell suspensions were prepared from spleen and liver. Single
cell suspensions were generated by physical disruption and passage through a .70 um cell filter
followed by red blood cell lysis. Cell suspensions were then washed once and stained in PBS
with 0.5% FBS with the following anti–mouse antibodies: FITC-conjugated anti-F4/80
(eBioscience) or PerCP-Cy5.5-conjugated F4/80 (eBioscience); phycoerythrin (PE)-conjugated
antibodies to CD11b (BD), Alex Fluor 647-conjugated CD206 (Serotec), PE-Cy5- conjugated
CD80 (B7-1) (eBioscience), and eFluor 450-conjugated MHC Class II (eBioscience). The
respective isotype-matched conjugated controls were purchased from eBioscience, BD, and
Serotec. Acquisition was performed on a FACSCalibur or Fortessa and the dedicated software
CellQuest (BD). Data were analyzed with FlowJo 7.5.5 software (Tree Star).
Statistics
All data represent mean ± SD. Data were analyzed using two-tailed Student’s t test, with a P
value of <0.05 set as statistically significant. *p<0.05 **p<0.01, ***p<0.001
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4.5 Results
PLC2 regulates pro-inflammatory gene transcription in macrophages
We previously found that PLC2-/- mice are protected from inflammation in the K/BXN model
of serum-transfer arthritis which is strongly dependent on the neutrophil pro-inflammatory
response. Mechanistically, PLC2 is required for neutrophil degranulation in response to
integrin-mediated adhesion (14). We hypothesized that PLC2 modulates a similar proinflammatory pathway downstream of integrin in macrophages. WT and PLC2-/- bone marrow
macrophages (BMMs) were plated on the generic integrin ligand Arg-Gly-Asp (pRGD) for 2 and
4 hours. WT BMMs significantly upregulate transcript levels of TNF-, IL-1, and IL-6 after 2
and 4 hours of integrin adhesion, compared to WT cells in suspension (Figure 4.1 A ). This
inflammatory response is abrogated in BMMs lacking PLC2-/-. NF-kB is a transcription factor
critical for induction of inflammatory responses and cytokine production. We hypothesized that
PLC2 modulates inflammatory cytokine transcription via NF-kB activation. In WT cells,
integrin ligation induces rapid phosphorylation of IKB, an indicator of NF-kb pathway
induction (Figure 4.1 B). IKB phosphorylation is significantly blunted in PLC2-/- BMMs,
however. Thus, downstream of integrin ligation, PLC2 induces NF-kB activation to turn on
inflammatory cytokine production.
In the osteoclast, both PLC2’s catalytic and scaffolding motifs are necessary to generate
downstream signal transduction (15, 17) To determine which domain(s) of PLC2 are mediating
this NF-kB activation, we expressed full-length PLC2 or PLC2 constructs harboring mutations
in the catalytic or SH2 scaffolding domain in PLC2-/- BMMs. Expression of full-length PLC2
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rescued IKB phosphorylation in PLC2-/- cells stimulated on pRGD. Cells expressing
catalytically inactive PLC2, however, were still unable to activate NF-kB, while the SH2
domain appears to be dispensable in this pathway (Supplementary Figure 4.1). Collectively,
these data suggest that PLC2 controls the induction of a pro-inflammatory pathway in activated
macrophages.
Tmem178 is a PLC2-dependent gene in inflammatory macrophages
To identify specific downstream modulators of this PLC2-dependent pro-inflammatory
pathway, we performed a gene array experiment comparing WT and PLC2-/- BMMs plated on
pRGD. Transmembrane protein 178 (Tmem178) was highly induced in WT BMMs after 4 hours
of adhesion (Figure 4.1 C). PLC2-/- BMMs, however, failed to upregulate Tmem178 transcript.
We next asked what other inflammatory stimuli can induce Tmem178 expression. Confirming
the gene array, Tmem178 transcript levels are significantly upregulated in WT BMMs plated on
pRGD. LPS treatment also strongly upregulates Tmem178 (Figure 4.1 D). On the other hand,
Tmem178 expression is low in neutrophils, dendritic cells (DCs), and is not detected in T cells.
These results position Tmem178 as a specific modulator of the pro-inflammatory macrophage,
acting downstream of PLC2.
Tmem178-/- mice are more susceptible to sepsis
We have previously described the impaired inflammatory response of PLC2-/- mice in
the context of arthritis (14). PLC2 has previously been shown to mediate inflammatory cytokine
production in LPS-treated macrophages (18). To evaluate the role of Tmem178 during an
inflammatory response in vivo, we utilized the endotoxin model of sepsis. Strikingly, Tmem178-
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/- mice rapidly succumbed to systemic LPS, with the majority of knock-out mice dying within 16
hours of challenge (Figure 4.2 A). This mortality was associated with a significant increase in
TNF- levels detected in the serum 2 hours post-LPS administration (Figure 4.2 B). Tmem178-/mice do not present with spontaneous inflammation in vivo, supporting that Tmem178 may be
most highly expressed and physiologically important during an immune challenge (Supplemental
Figure 4.2). These in vivo data indicate that Tmem178 is a negative regulator of inflammation, in
contrast to the pro-inflammatory role played by PLC2.
Tmem178 restrains inflammatory cytokine production by macrophages
To confirm that Tmem178 affects the macrophage inflammatory response in vitro, we
measured inflammatory cytokine production by WT and Tmem178-/- BMMs in vitro in response
to adhesion and LPS. Confirming our previous observations, WT BMMs plated on pRGD
increase TNF-, IL-6, and IL-1 mRNA expression (Figure 4.2 C). Each of these cytokines were
each markedly increased in Tmem178-/- BMMs however. Similarly, LPS treatment increases
inflammatory cytokine transcription in WT BMMs as expected, but this response is even
amplified in Tmem178-null BMMs (Figure 4.2 D). Together with our previous expression
profiles and in vivo results, these data indicate that Tmem178 acts in a negative feedback loop to
dampen inflammatory signaling in the macrophage.
Tmem178 targets Ca2+-NFAT signaling to repress inflammation
We next wanted to examine the mechanism by which Tmem178 restrains the proinflammatory response. Adhesion and TLR ligation both activate NF-kB and MAPK signaling
cascades. We next asked if Tmem178 affects these pathways to modulate inflammation. We first
plated WT and Tmem178-/- BMMs on pRGD to up-regulate Tmem178 expression in WT cells,
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and then stimulated the cells with LPS. We find that p-JNK, p-ERK, and p-IKBinduction
occurs rapidly and equivalently in both genotypes (Figure 4.3 A). NFATc1, however, is higher in
Tmem178-/- cells prior to LPS stimulation. Activation via integrin or LPS alone also shows a
similar increase in NFATc1 (Supplementary Figure 4.3).
Multiple NFAT isoforms are expressed in macrophages and contribute to inflammatory
response (19). In addition to NFATc1, NFATc3 is also important to the inflammatory response.
Importantly, NFAT isoforms are regulated at the transcriptional level by binding to and autoamplifying expression at its own promoter. We measured NFAT transcripts in peritoneal
macrophages ex vivo, as well as in BMMs stimulated with LPS, and found that both NFATc1
and NFATc3 are higher in Tmem178-/- cells (Figure 4.3 B, C).
In basal conditions, NFAT is sequestered in the cytosol due to masking of its nuclear
localization sequence. The Ca2+/calmodulin-dependent phosphatase calcineurin dephosphorylates NFAT, inducing a conformational change to allow nuclear translocation. Thus,
cytosolic Ca2+ fluxes are essential to NFAT activation. We hypothesized that Ca2+ oscillations
may be amplified in the Tmem178-/- inflammatory macrophage. WT and Tmem178-/- BMMs
were stimulated with LPS for 16 hours, and then loaded with the Ca2+-binding dye Fura-2. We
used ratiometric confocal imaging to measure cytosolic Ca2+, as measured by Fura-2 emission
following alternating excitation at 340 and 380 nm. We found that Ca2+ fluxes were higher in
Tmem178-/- cells, and a greater percentage of cells display robust Ca2+ fluxes compared to WT
cells (Figure 4.3 D). Thus, Tmem178 appears to target intracellular Ca2+ signaling to regulate
inflammation.
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M1 and M2 macrophage populations participate in MAS
In order to evaluate the role of Tmem178 specifically in a clinically relevant,
macrophage-driven disease, we turned to macrophage activation syndrome (MAS). MAS bears
many clinical similarities to the inherited disease (fHLH), which is also characterized by
excessive macrophage infiltration and systemic inflammatory disease with a similar
inflammatory cytokine profile (20). Jordan et al previously established a mouse model of
fHLH/MAS utilizing perforin (prf)-/- mice infected with lymphocytic choriomengitis virus
(LCMV-WE). Prf-/- mice infected with LCMV recapitulate the pathology of MAS and fHLH
patients (21). Despite the expanded presence of macrophages in this disease, it is unknown if
macrophages are the drivers of disease through excessive antigen presentation and inflammatory
cytokine production, or if macrophages are futilely attempting to control the pathology. Thus, we
first wanted to evaluate the role of macrophages in this model. We administered clodronateloaded liposomes (CLL) to specifically deplete macrophages, and confirmed the depletion by
FACS of F4/80+ cells (Supplemental Figure 4.4). We administered CLL to prf-/- mice 2 days
prior to LCMV infection, and every 3 days thereafter for the course of infection. Because
virally-infected WT mice depleted of macrophages die due to liver failure (22), we used
liposomes containing PBS as controls in WT and prf-/- mice. As expected, 100% of LCMVinfected prf-/- mice died within 21 days (Figure 4.4 A). Prf-/- mice with macrophages depleted
by CLL survived for more than 40 days post-infection, similarly to WT mice. Serum cytokines
measured on day 10 of infection showed that macrophage depletion strongly reduces IFN- and
MCP-1 levels (Figure 4.4 B). We also wanted to know if macrophage depletion later in the
course of infection could cure prf-/- mice of HLH. We began CLL treatment on day 6 after
LCMV inoculation, as this was the time point when mice showed obvious signs of disease
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including weight loss, hunched posture, and ruffled fur. Surprisingly, mice treated on day 6 died
more rapidly, reaching 100% mortality by day 16 (Figure 4.4 C). From these data we
hypothesized that both pro- and anti-inflammatory macrophages are present during HLH, with
the latter population playing an essential role to limit the infection later in disease.
To examine this possibility, we characterized M1 and M2 macrophage populations during
the course of infection in prf-/- mice. The livers and spleens of mice were harvested after the
indicated days of infection. Both M1 (F4/80+MHC Class II + CD86+) and M2 (F4/80+CD206+)
populations increase in liver (Figure 4.4 D) and spleen (Figure 4.4 E). There is a significant and
transient increase in M2 macrophages by day 7 of infection in the liver and days 7-10 in the
spleen. These data suggest that an infiltrating population of anti-inflammatory macrophages is
important to control disease progression.
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4.6 Discussion
Current therapeutics to treat pathological bone loss are widely unsuccessful at addressing
both the resorptive and inflammatory components of disease. We have previously established the
fundamental role of PLC2 in regulating both osteoclast differentiation and bone resorption as
well as the immune cell compartment in arthritic disease (14, 17, 23). PLC2-specific targeting
to treat inflammatory bone loss is impractical due to its high homology with the ubiquitously
expressed isoform PLC1. Moreover, we know little about PLC2-dependent regulators of the
innate inflammatory response. Here we characterized Tmem178 as a PLC2-dependent negative
regulator of the pro-inflammatory macrophage which acts by repressing Ca2+ oscillations and
downstream NFAT activation. Tmem178 is also required in vivo to control and repress a
systemic inflammatory response. Ongoing studies will address the role of Tmem178 in MAS, a
complicating disorder of arthritis.
To understand how Tmem178 restrains inflammation, we examined signaling pathways
that are known to be activated by TLR signaling to promote inflammatory cytokine production.
Similar to our findings in the osteoclast, Tmem178 deletion did not affect NF-kB or MAPK
induction, but rather targets Ca2+ fluxes leading to NFAT activation. We found that both Nfatc1
and Nfatc3 isoforms are increased in Tmem178-/- BMMs. Ca2+ has long been recognized as an
absolutely essential second messenger for both adaptive and innate responses. Mechanisms of
calcium signaling in the context of immunity have largely been discovered and characterized in
the context of the T cell and B cell receptors (24). While not as closely studied, PLC2dependent Ca2+ pathways have previously been shown to regulate inflammatory cytokine
production in macrophages (25-29). Here we show that Tmem178 functions in a novel negative
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feedback loop downstream of PLCγ2 to repress inflammation, thus building on the
understanding of how intracellular calcium is regulated during an inflammatory response.
Importantly, calcineurin inhibitors are widely used as immunosuppressive drugs, and while
effective, this approach lacks specificity. Here we have characterized a novel and specific
intrinsic mechanism of targeting calcium signaling in macrophages.
Circulating and tissue-resident monocyte/macrophage populations can dictate the
immune response by producing a number of cytokines, both pro- and anti-inflammatory.
Macrophages have been segregated into “classically activated” M1 and “alternatively activated”
M2 subtypes. M1 macrophages are strongly pro-inflammatory and anti-tumorigenic through the
production of IL-1, TNF-, IL-6, and iNOS, as well as enhanced MHC Class II antigen
presentation capacity. On the other hand, M2 macrophages produce arginase and IL-10 to
resolve inflammation and promote tissue repair (30). The relative contribution of M1 and M2
populations in systemic auto-inflammatory disorders including sJIA is not well understood.
Although sJIA patients have an overall expansion in activated monocytes, they present a mixed
M1 and M2 phenotype both on an overall and single cell level (31, 32). Thus, a better
understanding of the intrinsic regulatory mechanisms that control macrophage inflammatory
responses could be informative to understanding the molecular pathogenesis of sJIA. Here we
identify a novel negative feedback loop mediated by Tmem178 that is enacted to control the proinflammatory macrophage response.
The large majority of mortalities associated with sJIA are due to the confounding
disorder MAS. MAS patients present with a sudden onset of fever, pancytopenia, and very high
levels of inflammatory cytokines, TNF-, IL-1, IL-6, IL-18, as well as IFN-g in the serum.
Strikingly, there is a huge increase in macrophages in the spleen, liver, and bone marrow of these
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patients. Importantly, MAS is clinically nearly identical to familial hemophagocytic
lymphohistiocytosis (fHLH), an inherited condition owing to a genetic defect in cytotoxic killing
by T-cells and NK cells. In particular, patients have been identified with mutations in perforin,
granzyme B, and vesicular trafficking components required for cytotoxic granule release. While
some sJIA patients also harbor such genetic mutations that predispose them to MAS, it is not the
case for all patients. The cause of MAS is unknown, and other than inherited conditions, there
are currently no predictive indicators of which subset of sJIA patients will develop MAS. We
have previously shown that Tmem178 is dysregulated in the context of sJIA, and defective
Tmem178 expression is associated with excessive osteoclast development. We now show a role
for Tmem178 in controlling inflammation as well, positioning Tmem178 as an essential
regulatory component in both the inflammatory and erosive arms of sJIA.
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4.8 Figure Legends
Figure 4.1 PLC2 regulates pro-inflammatory gene transcription in macrophages
A. WT and PLC2-/- BMMs were lifted and re-plated on integrin ligand for 2 and 4 hours.
Inflammatory cytokines IL-6, IL-1, and TNF- were measured by quantitative RT-PCR,
with gene expression normalized to the housekeeping gene cyclophilin.
B. WT and PLC2-/- BMMs were lifted and re-plated on integrin ligand for the indicated
time points. Whole cell lysates were subjected to SDS-PAGE and Western blot to detect
p-IKB as a read-out of NF-kB activation.
C. Gene array of WT and PLC2-/- BMMs plated on integrin ligand pRGD for 2 and 4
hours. Tmem178 is upregulated in adherent WT BMMs but not highly detected in
PLCg2-/- BMMs
D. Quantitative RT-PCR of Tmem178 transcript in untreated WT BMMs or stimulated via
integrin or TLR, as well as in bone marrow-derived neutrophils, bone marrow dendritic
cells (DC) and T cells.
Figure 4.2. Tmem178 negatively regulates the pro-inflammatory response of macrophages
A. WT and Tmem178-/- mice were treated with 25 mg/kg LPS administered IP and
monitored for survival. n = 12 WT, 17 Tmem178-/B. Serum TNF-a was measured 2 hours after LPS injection in (A).
C-D.Quantitative RT-PCR of inflammatory cytokine transcripts in WT and Tmem178-/BMMs plated on integrin ligand (C) or treated with 1 ug/ml LPS. TNF-, IL-6 and IL-1
expression was normalized to the housekeeping gene cyclophilin.
Figure 4.3. Tmem178 reduces Ca2+ fluxes leading to NFAT induction in pro-inflammatory
macrophages
A. WT and Tmem178-/- BMMs were plated on pRGD for 8 hours, and then stimulated with
1 ug/ml LPS for the indicated time points. Whole cell lysates were separate by SDSPAGE and immunoblotted with the indicated antibodies to detect MAPK and NF-kB
pathway activation, as well as NFATc1 induction. Pyk2 was detected as a loading
control.
B-C. Nfatc1 and Nfatc3 transcripts were measured by quantitative RT-PCR with values
normalized to cyclophilin in resident peritoneal macrophages (B, n = 4/genotype) or
BMMs stimulated with 1 ug/ml LPS for 4 hours (C).
D. Intracellular Ca2+ fluxes in single BMMs treated with 1 ug/ml LPS for 16 hours prior to
imaging. Each line traces a single cell, representative of 3 independent experiments.
Figure 4.4. M1 and M2 macrophage populations participate in a mouse model of
MAS/fHLH
A. WT and prf-/- mice were infected with LCMV-WE. Prf-/- mice were depleted of
macrophages by systemic administration of clodronate-loaded liposomes (CLL) prior to
infection. n = 5/group
B. Serum IFN- and MCP-1 were measured in mice in (A) on day 10 of infection.
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C. WT and prf-/- mice were infected with LCMV-WE. Prf-/- mice were depleted of
macrophages by systemic administration of CLL beginning on day 6 of infection. n =
5/group
D-E. Prf-/- mice were infected with LCMV-WE to induce MAS/fHLH. Liver and spleen
were harvested after the indicated days of infection to measure surface expression of
markers for M1 macrophage (F4/80+MHC Class II + CD86+) and M2 macrophages
(F4/80CD206) n = 5/group
Supplemental Figure 4.1 PLC2 catalytic activity is required for adhesion-induced NF-kB
activation
BMMs were plated on pRGD for the indicated time points. NF-kB induction in PLC2-/BMMs transfected with WT-PLC2 (left panels), PLC2 catalytic inactive mutant (middle
panels), or PLC2 SH2 mutant (right panels).
Supplemental Figure 4.2. Tmem178-/- mice do not display an inflammatory phenotype in
basal conditions
A. Serum cytokine levels in WT and Tmem178-/- mice in basal conditions. WT n = 5,
Tmem178-/- n = 9
B-C. M1 and M2 macrophages detected in the peritoneum and spleen of un-manipulated
WT and Tmem178-/- mice
Supplemental Figure 4.3. Tmem178 specifically affects NFATc1 in pro-inflammatory
macrophages
A. WT and Tmem178-/- BMMs were stimulated on LPS for the indicated time points.
Whole cell lysates were separate by SDS-PAGE and immunoblotted with the
indicated antibodies to detect MAPK activation, as well as NFATc1 induction. Actin
was detected as a loading control.
B. WT and Tmem178-/- BMMs were plated on pRGD for the indicated time points.
NFATc1 was detected by Western blot of whole cell lysates. Total ERK was
detected as loading control.
Supplemental Figure 4.4. Confirmation of macrophage depletion by clodronate loaded
liposomes
Flow cytometry to detect F4/80+ cells in the spleen of PBS- or clodronate-treated mice.
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5.1 Conclusions and future directions
In this work, we have identified Tmem178 as a new PLCγ2-dependent gene and
demonstrated the first known function of Tmem178 in any cell type. Tmem178 is not
similar to any other “Tmem” molecules, or any other transmembrane proteins expressed
in the OC or macrophage. Other than its Claudin-2 domain, which is not known to harbor
any intrinsic function, Tmem178 does not contain any conserved structural domains or
similarity to other Ca2+-related proteins. Moreover, we found that Tmem178 expression
is induced downstream of PLC2-dependent pro-osteoclastogenic and pro-inflammatory
pathways, but Tmem178 actually acts in a negative feedback loop to restrain both
osteoclastogenesis and inflammatory cytokine production. Thus, the findings presented in
this thesis were neither obvious nor expected.
Current therapeutics to treat pathological bone loss are widely unsuccessful at
addressing both the resorptive and inflammatory components of disease. Moreover, even
patients who respond favorably to anti-inflammatory agents can suffer from progressive
joint disease. Thus, an essential question in the field is how we could simultaneously
target activation of both immune cells and osteoclasts. Our lab previously undertook
studies to identify common signaling components shared in the osteo-immune system and
successfully identified PLCγ2 as such a critical signaling molecule. PLCγ2-/- mice are
protected from inflammatory bone loss due to a blockade in both bone resorption as well
as immune cell activation. While PLCγ2 seems an appealing therapeutic target, its
extensive homology with other PLC isoforms presents a challenge for specific targeting
in vivo.
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We devised a strategy to specifically target PLCγ2 via its unique SH2 domains.
By ectopically expressing a construct comprised of the tandem SH2 domains of PLCγ2,
we were able to inhibit osteoclastogenesis in vitro by impeding protein scaffolding at
RANK. Importantly, expression of this (N+C)-SH2 construct in vivo via an adenoviral
vector also successfully repressed inflammatory osteolysis (1). This approach, however,
did not block inflammation in vivo. Therefore, we must focus on characterizing unique
downstream effectors of PLCγ2 which modulate osteo-immune activation.
Using a gene array approach to identify PLCγ2-dependent genes, we found that
the uncharacterized protein Tmem178 was highly induced in stimulated WT cells but not
in PLCγ2-/- cells. Tmem178 expression is upregulated in both osteoclasts in response to
RANKL, as well as in macrophages in response to adhesion or TLR ligation. Importantly,
Tmem178 expression appears to be limited to these compartments, and we do not
detected Tmem178 transcript in osteoblasts, neutrophils, or T cells. Thus, Tmem178 may
be the specific, PLCγ2 downstream effector we were seeking which could control osteoimmune activation. In striking contrast to the osteopetrotic PLCγ2-/- mice, Tmem178null mice present with low bone mass in basal conditions and exaggerated osteoclast
formation and bone loss during inflammatory arthritis. In vitro, Tmem178-/- cells display
an enhanced ability to form osteoclasts. Thus, Tmem178 is a surprising negative
regulator of osteoclastogenesis. Mechanistically, Tmem178 specifically targets NFATc1
induction in osteoclasts by controlling ER Ca2+ mobilization.
Ca2+ is a ubiquitous signaling mediator in nearly all cell types and thus calcium
signaling must be regulated in all cell types, so why is Tmem178 so unique and its
expression seemingly very limited? In primary cells, elegant studies have been performed
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to characterize Ca2+ signaling mechanisms in the context of the T and B cell receptor, or
innate immune cells such as mast cells. In these cell types, receptor ligation induces an
acute and transient spike in cytosolic Ca2+, leading to an immediate signaling event. This
is not the case in OCs, however, where intracellular Ca2+ fluxes are sustained over a
longer time course. Moreover, the amplitude and duration of dynamic Ca2+ signals have
been shown to differentially modulate activation of various transcription factors. The OC
uses Ca2+ to turn on NFATc1 activation. NFAT proteins have enhanced Ca2+ sensitivity
compared to other transcription factors such as NF-kB or JNK, which enables NFAT
transcriptional activation by low Ca2+ levels (2). In the OC, a low but prolonged Ca2+
signal induces NFATc1 nuclear translocation and long-lasting nuclear localization
throughout osteoclastogenesis. Therefore, it is conceivable that the OC requires
additional regulatory mechanisms to carefully buffer ongoing and subtle changes in
cytosolic Ca2+.
Interestingly, Tmem178 couples to the ER Ca2+ sensor Stim1, which is most wellcharacterized for its coupling to Orai1 to activate store-operated Ca2+ entry (SOCE).
Surprisingly, we did not detect a direct effect of Tmem178 expression on SOCE, nor did
we find that Tmem178 interacts with Orai1 or modulates Orai1-Stim1 coupling. These
findings that Tmem178 associates specifically with Stim1 independent of SOCE raise the
possibility that Stim1 is also participating in ER Ca2+ release in OCs. In recent studies,
Stim1 has been shown to play a possible role in affecting ER Ca2+ release through the
IP3R channels (3, 4). IP3R activity is highly regulated by multiple adaptor proteins as
well as kinases which phosphorylate IP3R to increase its sensitivity to IP3 (5). We have
not been able to detect an association between Tmem178 and endogenous IP3Rs,

152

however. It is possible that Tmem178-Stim1 is affecting Ca2+ release through the
ryanodine receptor whose regulation is less well-understood than IP3Rs (6).
Further studies are underway to understand which functional domain(s) of
Tmem178 are important to its function and coupling to Stim1, and vice versa. While very
little information is available about Tmem178 structure, we know it contains 1 claudin-2
domain. Structure/function studies showed that the C-terminal tail of claudin-2 domaincontaining proteins is required for their function, and phosphorylation of a Serine residue
in the C-terminus was also shown to promote membrane localization and control ion
transport (7-9). Therefore, we have generated a C-terminus truncation mutant of
Tmem178 to evaluate its ability to bind to Stim1 and repress ER Ca2+ release.
Extensive structure-function experiments delineated the mechanism of Stim1
activity during SOCE. In the ER luminal portion of the protein, Stim1 harbors a Ca2+binding EF hand as well as a SAM domain which facilitates protein-protein interactions.
When ER Ca2+ stores are depleted, Ca2+ dissociates from the EF hand and causes EF-hand
and SAM domains to interact between Stim1 molecules. This induces a conformational
change in the cytoplasmic domain leading to the unfolding and extension of the Cterminus; this is the “activated” Stim1 dimer. Stim1 continues to oligomerize as it is relocalizing to the ER-plasma membrane junction. At the C-terminus of Stim1, the STIMOrai1 activating region (SOAR) binds and activates Orai1, allowing CRAC channel
activation (10). The domains of Stim1 which interact with IP3Rs have not been
identified. By expressing the individual domains of Stim1, we can determine which
regions are necessary and sufficient to interact with Tmem178. It is also necessary to
understand if the same regions of Stim1 which modulate Orai1 activation, namely the
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SAM and SOAR domains, are necessary to associate with Tmem178. Moreover, we have
not assessed the temporal or spatial aspects of the Tmem178-Stim1 interaction. In future
live cell imaging studies, we must understand when the Tmem178-Stim1 interaction
occurs downstream of receptor signaling, and how this affects Stim1 translocation that is
necessary for SOCE. We have observed that Tmem178 does not affect SOCE, suggesting
that perhaps separate pools of Stim1 exist in the ER to regulate different intracellular
Ca2+ events.
Having confirmed that Tmem178 is a negative regulator of osteoclastogenesis in
vitro and in vivo, we sought a role for Tmem178 in human disease. We turned to
systemic juvenile idiopathic arthritis (sJIA), as it is a predominantly monocyte-mediated
auto-inflammatory disordered associated with progressive joint disease. Using the plasma
from sJIA patients, we found that Tmem178 is strikingly down-regulated by sJIA plasma,
permitting more exuberant osteoclastogenesis. Importantly, patients who presented with
active erosive disease were each associated to significantly down-regulated Tmem178
levels in vitro. While our sample size at this point is too small to draw a correlation
between defective Tmem178 expression and active joint erosion, it will be interesting in
the future to see if Tmem178 levels could be a predictive biomarker of patients who will
develop progressive joint disease.
sJIA is unique from other JIA subtypes in its dependence on the innate immune
response, specifically monocytes, in disease pathogenesis with a limited role of the
adaptive immune response. sJIA is not associated with MHC allele susceptibility or
rheumatoid factor. In fact it is so distinct from other JIA subtypes that the categorization
is considered by some to be a misnomer. Intriguingly, M2-like monocytes appear during
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episodes of disease flare and persist into the transition to a quiescent state, suggesting that
this M2 population arises in an attempt to ameliorate the systemic inflammatory
environment (11, 12). In fact, it is still unknown whether the excessive pro-inflammatory
response or defective anti-inflammatory response truly underlies the pathologies of sJIA.
We know that Tmem178 expression is specific to activated myeloid cells,
including macrophages exposed to inflammatory stimuli such as TLR ligands. The trigger
of sJIA is unknown, but endogenous TLR ligands are possible activators of the autoinflammatory reaction. In studying the role of Tmem178 in the pro-inflammatory
macrophage, we found that Tmem178 limits inflammatory cytokine release in response to
both adhesion and LPS stimulation. Similarly, Tmem178-/- mice succumb faster to
endotoxin-induced sepsis. These data position Tmem178 as a negative regulator of the
pro-inflammatory macrophage response. While we have found that Tmem178 is downregulated by sJIA serum during osteoclastogenesis, we have yet to characterize the role of
Tmem178 in the inflammatory component of sJIA. It is possible that Tmem178
expression is also decreased in circulating inflammatory monocytes of sJIA patients. This
reduction of Tmem178 would ramp up the pro-inflammatory response and hinder the
anti-inflammatory attempts of M2-like monocytes. In these conditions, Tmem178 levels
may also be a marker of the subset of sJIA patients who develop an acute, potentially
fatal disorder known as macrophage activation syndrome (MAS).
While the cause of MAS is uncertain, it is possible that a dysregulated adaptive
immune response to an infectious trigger stimulates the over-active macrophage
population. It is actually unknown how the macrophage is participating in disease. It is
possible that macrophages are attempting to control the adaptive immune response. On
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the other hand, macrophages may be driving the pathology by facilitating excessive
antigen presentation to T cells and producing inflammatory cytokines. The specific
contribution of M1 and M2 macrophages during a course of MAS has not yet been
studied.
MAS bears many clinical similarities to the inherited disease familial
hemophagocytic lymphohistiocytosis (fHLH), which is also characterized by excessive
macrophage infiltration and systemic inflammatory disease with a similar inflammatory
cytokine profile (13). We used a mouse model of fHLH to define the requirement of
macrophages in this disease (14). In preliminary studies, we have found that both M1
and M2 macrophage populations increase during the LCMV-induced model of MAS. In
fact, limiting the M1 response early in disease is sufficient to protect mice from disease,
while eliminating the infiltrating anti-inflammatory M2 population accelerates mortality.
Could Tmem178 be participating in these distinct phases of macrophage activity? To this
end, we have generated Tmem178-perforin double knock out mice in which we can
induce MAS. If Tmem178 is important to the attempts to control MAS early in the course
of disease, the double knock out mice will succumb faster than perforin-null mice alone.
If so, it would be interesting to measure Tmem178 transcript levels in the monocytes of
sJIA patients who go on to develop MAS.
In sum, this work defines the function of Tmem178 as novel regulator of osteoimmune activation. In contrast to our expectations, these studies identified a novel
negative feedback loop acting via Ca2+ to control myeloid cell activation. As this is the
first work describing Tmem178 in any cell type, there are many more studies to be done
to fully understand the function of Tmem178 in homeostasis and disease, particularly in
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sJIA. Most importantly, we identified a new pathway of Ca2+ regulation in myeloid cells
as a mechanism that can control both joint erosion and excessive inflammation.
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